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1 Introduction 
 
1.1 State of the art and challenges in biomaterial development for application in skin and 
bone 
 
The majority of skin wounds and bone fractures heal well without the need for major 
intervention due to the high regenerative potential of these tissues, especially in younger 
people. Large bone defects, as observed after bone tumor resections and severe non-union 
fractures, on the other hand, are not provided with a template for an orchestrated regeneration 
and require surgical intervention [1], and skin wounds that have failed to progress through the 
normal stages of healing enter a state of pathologic inflammation resulting in delayed acute or 
chronic wounds [2]. Due to the demographic change, 20% of the population in Europe will be 
over 65 years in 2025 [3]. In the US, adults over the age of 60 will outnumber younger people 
by 2050 [4]. A longer life expectancy goes along with an increased risk of age-related 
pathologies including chronic wounds, impaired fracture healing and the associated clinical 
and socioeconomic burdens [5]. For instance, approximately 1–2% of the population of the 
United States and Europe is currently affected by chronic wounds, requiring a financial 
commitment of 2–4% of total health budgets from governments [6]. There are various factors 
associated with aging which additionally impair the healing capacity: for example a decline of 
sex steroid hormones, malnutrition, immobilization, psychological stress, medication and 
comorbidities such as diabetes, peripheral arterial disease, chronic venous insufficiency [5] 
and osteoporosis [7]. Currently the gold standard treatment of bone fractures is the use of 
autogenous cancellous bone [8] due to its osteogenic, osteoconductive and osteoinductive 
properties and the lack of disease transmission or immunogenicity when utilized [9]. 
Transplanting autologous bone has the best clinical outcome with a success rate of 50 - 80% 
[10]. However, its disadvantages are a limited availability, the need for two operations, chronic 
donor site pain and additional costs [11]. The application of growth factors like bone 
morphogenetic protein (BMP)-2 and BMP-7 is an alternative treatment, inducing bone 
formation in tibial non-unions comparable to autologous bone graft [12]. Though, Garrison et 
al. found no difference between transplanting autologous graft and treatment with BMPs [13].
 A gold standard in chronic wound management is the split-thickness autograft 
consisting of epidermis and superficial dermis that is harvested from a remote area of healthy 
skin and transferred to the excised wound [14,15]. However, the procedure has several 
limitations as well, including the quantity of available donor skin and the risk of complications 
comprising pain and donor-site infection [16,17]. Alternative methods promoting wound healing 
such as growth factor delivery also need significant improvement in order to heal wounds in an 
appropriate manner without delaying [14].  
Utilizing biomaterials is considered to be very promising in treating critical-size bone defects 
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and acute or chronic skin wounds. A biomaterial was defined as ‘a non-viable material used in 
a medical device, intended to interact with biological systems’ in the first Consensus 
Conference of the European Society for Biomaterials (ESB) in 1976. The ESB’s current 
definition, however, is a ‘material intended to interact with biological systems to evaluate, treat, 
augment or replace any tissue, organ or function of the body’ [18], illustrating that biomaterials 
developed from solely interacting with the body to influencing biological processes towards the 
goal of tissue regeneration by productive interaction with biological molecules or cells. 
Materials for the treatment of injuries should ideally have biological and mechanical properties 
similar to their native counterparts and should fully incorporate into the remodeling process of 
skin and bone [19,20].   
Bone substitutes currently used are summarized in Table 1.1. Concerning skin regeneration 
most of the biomaterials in clinical use can be divided into two categories: synthetic materials, 
which are made up of acellular materials, and natural ones, containing cells (Table 1.2). Natural 
skin substitutes can be further classified into three types: epidermal substitutes with no dermal 
components, dermal substitutes, and bilayers containing both dermal and epidermal 
components [21].   
The main advantage of using biomaterials for replacement of skin or bone tissue is that the 
need for a donor site area required to harvest an autograft can be reduced or eliminated, thus 
reducing the total number of surgical procedures and patient hospitalization time [22,23].
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Table 1.1. Clinically relevant bone grafting materials for bone repair and regeneration (adapted and modified from [24]) 
Bone grafting 
materials 
Examples Advantages Disadvantages 
Polymers 
Natural 
 
 
 
 
Synthetic 
 
- Protein: collagen, fibrin, gelatine, silk fibroin 
- Polysaccharides: hyaluronan, chondroitin 
sulfate, cellulose, starch, alginate, agarose, 
chitosan, pullulan, dextran 
 
- Poly-glycolic acid (PGA) 
- Poly-lactic acid (PLA) 
- Poly-(ε-caprolactone) (PCL) 
- Poly-(lactide-co-glycolide) (PLGA) 
- Poly-hydroxyethylmethacrylate (poly-HEMA) 
 
- Biodegradability 
- Biocompatibility 
- Biofunctionality 
- Unlimited source (some of them) 
 
- Biodegradability 
- Biocompatibility 
- Versatility 
 
- Low mechanical strength 
- High rates of degradation 
- High batch to batch 
variations 
 
- Low mechanical strength 
- High local concentration of 
acidic degradation products 
 
Ceramics 
 
Calcium-
phosphate 
 
 
 
Bioglasses 
and  
glass-
ceramics 
 
Others 
 
 
- Coralline or synthetic hydroxyapatite (HAp) 
- Silicate-substituted HAp 
- β-Tricalcium phosphate (β-TCP) 
- Dicalcium phosphate dehydrate (DCPD) 
 
- Silicate bioactive glasses  
(45S5, 13-93) 
- Borate/borosilicate bioactive glasses 
(13-93B2, 13-93B3, Pyrex®) 
 
- Alumina ceramic (Al2O3) 
- Zirconia ceramic (ZrO2) 
 
 
- Biodegradability 
- Biocompatibility 
- Biofunctionality 
- Osteoconductivity 
 
- Osteoinductivity (subject to 
structural and chemical 
properties) 
 
 
 
- Brittleness 
- Low fracture strength 
- Degradation rates difficult to 
predict 
Metals - Titanium and its alloys 
- Cobalt 
- Stainless steel 
- Magnesium and its alloys 
- Excellent mechanical properties 
(high strength and wear 
resistance, ductility) 
- Biocompatibility 
- Lack of tissue adherence 
- Corrosion 
- Risk of toxicity due to 
release of metal ions 
Composites - Calcium-phosphate coatings on metals 
- HAp/poly-(D,L-lactide) 
- HAp/chitosan-gelatin 
- Combinations of the above - Combination of the above 
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Table 1.2. Commercially available biomaterials for wound healing applications (adapted and modified 
from [21]). 
Skin substitute Composition Clinical examples 
Synthetic skin 
substitutes 
acellular materials, function 
primarily as barriers to fluid loss 
and microbial contamination 
AllodermTM, DermaSpanTM, 
FlexHDTM, SurgimendTM, IntegraTM, 
BiobraneTM, PuraplyTM 
Natural skin 
substitutes 
 
 
 
epidermal 
 
dermal 
 
bilayer 
tissue engineered skin, cultured 
allogeneic or autologous cell 
suspensions or sheets used alone 
or along with a dermal matrix 
 
keratinocytes  
 
fibroblasts  
 
fibroblasts and keratinocytes 
 
 
 
 
 
 
EpiCelTM 
 
TranscyteTM, DermagraftTM, 
denovoDermTM  
ApligrafTM, OrCelTM, TiscoverTM 
StratagraftTM, denovoSkinTM 
 
1.2 Extracellular Matrix (ECM) components as promising candidates for the design of 
functional biomaterials 
 
1.2.1 ECM 
 
The ECM is a three-dimensional, non-cellular network that consists of structural and functional 
molecules synthesized by local cells of each tissue (Figure 1.1) [25,26]. It provides not only 
structural support for cells but also biochemical cues to guide tissue development, maintain 
homeostasis and direct regeneration [27]. The importance of ECM function is illustrated by the 
broad range of tissue defects and embryonic lethality caused by mutations in genes that 
encode its components [28,29]. It consists of around 300 proteins and contains collagens and 
elastin to provide flexibility [30]. Collagens are a large family of triple helical proteins 
ubiquitously found in the body, conserved in all multicellular animals [31], and the most 
abundant proteins in the ECM [32]. They play an important role in cell adhesion and migration, 
tissue morphogenesis as well as tissue scaffolding and repair [32]. The majority of tissues in 
the human body contains a combination of collagen subtypes, with types I–IV being the most 
ubiquitous [33].   
Proteoglycans (PGs) and hyaluronic acid (HA) are interspersed among the collagen fibrils 
exerting a space-filling and lubricating function due to their high water-binding capacity. PGs 
are glycosylated proteins that consist of a core protein and covalently attached 
glycosaminoglycan (GAG) chains [32] which bind mediator proteins like growth factors, 
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proteases and protease inhibitors, thereby influencing their activities.   
Glycoproteins like fibronectins or laminins regulate cell adhesion and signaling between cells 
and ECM via interaction with integrins [32]. These molecules interact with each other as well 
as with the producing cells.  
The specific composition and distribution of ECM constituents as well as their chemical 
modification depends on the tissue as well as on the physiological state and defines tissue 
properties regarding mechanical characteristics and the potential to bind growth factors and 
cytokines [19,25].  
 
Figure 1.1. Schematic overview of the extracellular matrix composition (adapted and modified from [34]). 
The ECM is constantly rebuilt and remodeled by cells through synthesis, degradation, 
reassembly and chemical modification making a tight regulation of these processes important 
to maintain tissue homeostasis, especially in response to injury [35]. Dysregulation of ECM 
remodeling is associated with pathological conditions and can promote disease progression. 
For example, abnormal ECM deposition and stiffness are linked to fibrosis and cancer [36], 
and excessive ECM degradation is observed in osteoarthritis [37].   
Among biomaterials for skin replacement, substitutes composed of extracellular matrix (ECM) 
represent the majority of novel products, highlighting the significance of the ECM in providing 
important cues for healing processes [38].  
IntegraTM for example contains a dermal analog composed of bovine collagen and the GAG 
chondroitin-6-sulfate as well as a synthetic epidermal analog composed of a silicone polymer. 
The silicone layer provides a functional barrier which is removed upon dermis vascularization 
and replaced by a thin autograft layer, while the dermal layer serves as a matrix for the 
infiltration of fibroblasts and other cells from the wound bed. As the collagen-GAG matrix is 
populated by these cells, it is gradually degraded and replaced by newly synthesized collagen 
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[39]. AllodermTM provides a matrix for dermal tissue remodeling similar to IntegraTM. However, 
it consists of a dermal matrix derived from human skin of cadaver that has been screened for 
pathogens and processed to remove epidermal components and all dermal cells. Another 
promising example is OrCel™, which contains both fibroblasts and keratinocytes derived from 
neonatal foreskin. It uses a type I collagen sponge as dermal matrix [40]. The improved healing 
observed in contrast to other biomaterials was attributed to the presence of the collagen 
sponge in combination with growth factors produced by the allogeneic cells [40]. 
 
1.2.2 Glycosaminoglycans (GAGs)  
 
GAGs are linear polysaccharides usually found covalently attached to core proteins forming 
PGs, except for HA. They are present in the ECM and on all animal cell surfaces. Based on 
the chemical structure of the backbone, GAGs can be classified into four groups: (1) HA, (2) 
chondroitin sulfate (CS)/dermatan sulfate, (3) heparan sulfate (HS)/heparin (Hep) and (4) 
keratin sulfate (Figure 1.2). They consist of repeating disaccharide units composed of N-acetyl-
hexosamine and a hexose or hexuronic acid [41]. GAGs can be distinguished into sulfated 
(CS/dermatan sulfate, HS/Hep, keratin sulfate) and non-sulfated (HA) polysaccharides [42].  
 
 
Figure 1.2. Schematic representation of the different native GAGs. Except for hyaluronan, GAGs are 
covalently attached to a protein core to form PGs, which vary in GAG number and type (adapted and 
modified from [41]). 
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Due to a complex biosynthesis that is tightly regulated in biological systems GAGs display a 
considerable structural diversity, which is determined by the expression pattern, assembly 
machinery and modifying enzymes making the GAG pool unique for each cell [43,44]. The 
degree of sulfation and the position of sulfate groups along the GAG chain enable them to 
selectively interact with a variety of ligands in a spatially and temporally controlled manner 
[41,43]. Because of their strong hydrophilic nature based on their extensive sulfation, GAGs 
have extended structures in aqueous solutions. They hold a large number of water molecules 
in their molecular domain, thereby occupying enormous hydrodynamic space in solution [41].
 Hep and HS are composed of repeating disaccharide units of uronic acid-(1→4)-D-
glucosamine [45–47]. They share a common biosynthetic pathway in which various changes to 
these subunits are made, resulting in a large number of complex sequences [48]. The uronic 
acid can be β-D-glucuronic acid (GlcA) or its C-5 epimer, α-L-iduronic acid (IdoA), which can 
be sulfated at the 2-O position. The glucosamine may be N-acetylated or N-sulfated and can 
contain further sulfation at the 3-O and 6-O positions. Modifications in HS, which can display 
over 2000 sulfation motifs, are restricted to specific domains (S-domains, 5-10 disaccharides) 
that are hyper variable and interspersed with poorly sulfated domains (A-domains) [41,49]. 
Despite of the structural similarities, Hep has a considerably higher degree of sulfation than 
HS with more homogeneously distributed sulfate groups along the chain [41]. HS is 
ubiquitously expressed on cell surfaces, in ECM and basement membranes, and has a broader 
range of physiological targets than Hep. The latter is localized primarily to specialized 
basophiles and mast cells [49] and is often used as a model compound for HS. Diverse 
sulfation motifs have also been found for CS, with sulfation occurring on each of the free 
hydroxyl groups. This results in 265 potential sulfation sequences encoded in one CS 
tetrasaccharide [49].   
GAGs participate in various physiological and pathophysiological processes due to their 
remarkable ability to interact with a number of important growth factors and functional proteins, 
which is particularly significant for Hep and HS [41]. Interactions are based on ionic and/or H-
bonding forces between the sulfate and carboxyl groups of the GAG and positively charged 
amino acid residues, mainly arginine and lysine, in the GAG-binding protein [47,50–52]. The 
specificity of the protein/GAG interaction is manifested at many different levels. Some proteins, 
such as antithrombin or bFGF, require very distinct modifications in HS for optimal interaction 
[53,54] whereas for other proteins, like interferon-γ, the specificity of the interaction resides in 
the domain structure of HS [55]. For other groups of protein, like thrombin, the interaction 
depends merely on charge density and therefore appears to be non-specific [56]. However, 
even a non-specific interaction has a profound physiological consequence. By binding and 
regulating the activities of GAG-binding mediator proteins, GAGs play a key role in cellular 
signaling [57,58]. Additionally, by interacting with proteins they can serve as a reservoir of 
regulatory factors that can be liberated by selective degradation of GAG chains [59,60]. GAGs 
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are of vital importance for regulating the interactions between cells and the extracellular matrix. 
They stimulate the adhesion of cells to ECM by binding to other matrix macromolecules such 
as laminin or fibronectin [42,61,62]. Consequently, sulfated GAGs are interesting tools for the 
design of functional biomaterials as they are able to bind mediator proteins, thereby modulating 
their bioactivity and thus influencing cell-cell as well as cell-matrix interactions. 
 
1.3 Impact of GAGs on healing processes 
 
1.3.1 GAGs in wound healing and fibrosis 
 
Wound healing is a complex interplay between various cell types, the ECM, cytokines and 
growth factors. This orchestrated process is characterized by distinct but overlapping phases: 
hemostasis, inflammation, cell migration and proliferation, wound contraction, and remodeling 
[63]. Immediately after injury coagulation and hemostasis take place [64–66] to stop bleeding, 
which involves vasoconstriction, platelet aggregation and blood coagulation [67]. During this 
phase a provisional wound matrix is formed. This is important for the invading cells that are 
needed in the later phases of wound healing [68,69].   
The first subset of cells entering the injury side are platelets, which release numerous different 
inflammatory cytokines and growth factors such as platelet-derived growth factor (PDGF), 
transforming growth factor (TGF)-β1 or epidermal growth factor (EGF), thereby promoting the 
inflammatory phase [63]. This phase aims to establish an immune barrier against invading 
microorganisms [70] and is characterized by increased capillary permeability and cell migration 
into the wound site [63]. Immune cells such as neutrophils and macrophages are recruited to 
the wound site in response to chemotactic cytokines such as TGF-β [71]. Neutrophils have 
antimicrobial functions and can eliminate denatured ECM components by releasing proteases 
[63], while monocytes transform into macrophages that clear the wound area of debris and 
microbes [63].   
The following proliferative phase is characterized by migration of fibroblasts and deposition of 
newly synthesized ECM that replaces the provisional network formed during hemostasis [70]. 
The leading events during this phase are re-epithelialization, angiogenesis and fibroplasia. In 
the latter one fibroblasts migrate, proliferate and produce ECM components, resulting in the 
formation of granulation tissue within the wound site. Fibroblast migration is mediated by TGF-
β1 and PDGF [63]. During granulation tissue formation fibroblasts differentiate into myofibro-
blasts that play the main role in wound contraction, which markedly promotes wound closure 
[63].   
Tissue remodeling is the final phase of wound healing responsible for the development of new 
epithelium and involves vascular regression, granulation tissue remodeling and new formation 
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of ECM components [70]. During this phase the type III collagen produced in the proliferative 
phase is replaced by the stronger type I collagen [68], tightly regulated by TGF-β [72], and the 
growth of capillaries declines so that vascular density of the wound returns to normal [2,73–75]. 
When fibroblasts differentiate to excessive numbers of myofibroblasts and collagen deposition 
increases, the normal tissue repair can evolve into a progressively irreversible fibrotic response 
[43,76]. TGF-β regulates almost all aspects of wound healing and an aberrant TGF-β signaling 
is related to pathological skin disorders like fibrosis.  
GAGs play an essential role in wound repair activity through all phases of the healing process 
[77]. They influence wound healing by providing a supporting scaffold and through their 
involvement in signaling, the latter affecting stimulation of cellular migration, adhesion, 
proliferation, differentiation as well as regulation of ECM organization and metabolism [77]. 
HS/Hep are abundant in acute wound fluid 24 – 72 h after injury. By binding several growth 
factors, including Hep-binding EGF [78], hepatocyte growth factor or basic fibroblast growth 
factor (bFGF), they regulate epithelial repair and neovascularization [79,80]. HS/Hep are 
indispensable for adhesive contractile signaling, resulting in myofibroblast formation and 
wound closure during the wound healing process [57,81,82]. Moreover, after skin damage the 
heparan sulfate proteoglycan (HSPG) syndecan-4 is upregulated on fibroblasts within the 
granulation tissue, which may suggest that it regulates wound healing [83]. 
 
1.3.1.1 The role of TGF-β1 and GAGs in wound healing and fibrosis 
 
TGF-β1 is a 25 kDa homodimeric protein that belongs to the TGF-β superfamily consisting of 
structurally and functionally related cytokines. Besides three different forms of TGF-β this 
protein family comprises the BMPs, activins, inhibins, nodals and growth differentiation factors 
[71,84–86]. These cytokines are known to regulate cell survival, proliferation and differentiation 
[87,88] and are produced by diverse cell types, e.g. platelets, fibroblasts, endothelial cells 
(ECs) and immune cells [63,87,89].  
TGF-β1 is synthesized as a latent complex of high molecular weight containing a latency-
associated peptide (LAP) region. After processing TGF-β1 remains covalently bound to LAP, 
forming the small latent complex which then binds to latent TGF-β binding protein (LTBP). This 
so-called large latent complex is secreted into the extracellular environment and consists of 
TGF-β, LAP and LTBP [90]. When LAP and LTBP are removed, which can occur dependent 
or independent of proteases, TGF-β1 becomes active and is able to bind its receptors [84,91–
93].  
By assembling heterotetrameric complexes of structurally related serine/threonine-kinase 
receptor pairs, TGF-β superfamily members signal across cell membranes in a distinctive 
manner [94]. TGF-βs interact exclusively with their receptors, whereas BMPs, activins and 
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nodals promiscuously share type I and type II receptors [94–97]. TGF-β receptor type II (TβR-
II) has a high affinity for TGF-β1 while TGF-β type I receptor (TβR-I) does not, in spite of having 
a ligand binding domain [95,98]. The different ligand affinities of TβR-I and –II dictate an 
ordered-sequential complex assembly [99]. First, TGF-β1 binds to TβR-II and they both form a 
composite interface for the recruitment of the low-affinity TβR-I [95–97]. TβR-II then trans-
phosphorylates TβR-I upon binding of TGF-β1 [94,100,101]. Subsequently, activated TβR-I 
phosphorylates the cytoplasmic effector proteins Smad2 and Smad3, resulting in the 
heteromeric Smad2/3 complex that binds to Smad4. The complex is translocated to the 
nucleus regulating the transcription of numerous target genes [84,102–104]. In addition, TGF-
β1 is reported to activate non-Smad signaling pathways, like the extracellular signal-related 
kinase 1/2 (Erk1/2), which belongs to the mitogen-activated protein kinase pathways [105].
 As already mentioned, TGF-β1 is found at high levels in the wound microenvironment 
and plays a critical role in all phases of wound healing. It promotes fibroblast chemotaxis, 
myofibroblast differentiation and stimulates fibroblasts to synthesize and contract the 
extracellular matrix [71,84]). TGF-β1 contributes to ECM remodeling by regulating not only 
synthesis but also degradation of the ECM, as it controls the expression of matrix-degrading 
enzymes like matrix metalloproteinases (MMPs) [106] and their inhibitors [107]. Excessive 
accumulation of ECM proteins caused by consistent overexpression of TGF-β1 during wound 
healing clinically manifests in fibrotic skin disorders like hypertrophic scarring, keloids and 
localized or systemic sclerosis [86,108,109]. As TGF-β1 is a key mediator of fibrosis it is an 
emerging target for developing anti-fibrotic therapies [110–112].   
TGF-β1 has a Hep-binding domain (HBD) and is known to interact with Hep and HS. Its activity 
is reported to be potentiated upon binding to these GAGs, either by binding specifically to TGF-
β1 and thereby antagonizing its inactivation by α2-macroglobulin (α2M), or by acting as a 
specific co-receptor for TGF-β1 receptor binding [113]. Furthermore, Hep/HS could mediate 
TGF-β1 bioavailability by controlling the deposition of LTBPs into the ECM. In addition, GAGs 
were shown to protect TGF-β1 from proteolytic degradation in vitro and prevent the formation 
of inactive complexes with α2M [114,115].   
GAG binding occurs at two distinct sites on the TGF-β1 dimer [114] located opposite to each 
other [116]. The interaction of TGF-β1 with sulfated HA (sHA) and CS derivatives has been 
demonstrated by Hintze et al. [117]. The binding strength is dependent on the degree of 
sulfation and the carbohydrate backbone structure. Highly sulfated HA (sHA3, three sulfate 
groups per repeating disaccharide unit) exhibited the strongest interaction with TGF-β1.  
The consequences of TGF-β1 interaction with sHA derivatives for its biological activity were 
investigated in vitro [118]. In human dermal fibroblasts, an impaired Smad2/3 translocation to 
the nucleus was observed in the presence of sHA3. In contrast to results with HS/Hep showing 
a potentiation of TGF-β1 activity [114], results of van der Smissen et al. proposed that sHA 
prevents the interaction of TGF-β1 with its receptors resulting in a decreased TGF-β1 
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downstream signaling. Results point to the anti-fibrotic potential of sHA derivatives regarding 
the potential inhibition of TGF-β1 activity in fibrotic disorders. However, the modulatory 
mechanism of GAG derivatives on the process of TGF-β1:receptor complex formation has still 
not been investigated experimentally. 
 
1.3.2 GAGs in angiogenesis 
 
Angiogenesis is the formation of new blood vessels from pre-existing vasculature. It describes 
an essential and dynamic process during wound and fracture healing [119,120]. Angiogenesis 
is tightly regulated involving an extensive interplay between cells, soluble factors and the ECM 
[121]. In a first step, angiogenic factors such as vascular endothelial growth factors (VEGFs) 
and fibroblast growth factors (FGFs) stimulate ECs to secrete effectors like proteases and 
plasminogen activators that degrade the ECM and allow the cells to invade the surrounding 
matrix [52,122]. Consequently, cells migrate and proliferate, which leads to the formation of 
solid EC sprouts into the stromal space (Figure 1.3). The EC sprouts then undergo a morpho-
functional rearrangement, giving rise to a functional capillary [123]. ECs deposit new ECM and 
secrete growth factors, such as PDGF, which in turn attracts supporting cells like pericytes that 
ensure the stability of the new vessel [124]. 
 
Figure 1.3. Schematic overview of angiogenic sprouting. In response to pro-angiogenic factors, some 
ECs can sprout (green), whereas others fail to respond (blue). The process is controlled by the balance 
between pro-angiogenic signals and factors that promote quiescence such as tight pericyte (PC, light 
grey) contact and certain ECM molecules (dark grey) (adapted and modified from [121]). 
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Besides its importance in physiological processes angiogenesis also plays a role in 
pathological conditions. Several diseases are characterized by excessive angiogenesis, such 
as tumor progression, rheumatoid arthritis or diabetic retinopathy [122].   
Sulfated GAGs are known to modulate angiogenesis by binding to almost all angiogenic growth 
factors, some pro-angiogenic receptors and anti-angiogenic inhibitors [52]. HSPGs are 
associated to the surface of ECs with 105-106 molecules/cell [52]. The most represented 
HSPGs on ECs are syndecans and glypicans, while perlecan is the most common HSPG in 
the endothelial ECM [61,125]. HSPGs also exist in a soluble form following their mobilization 
from the cell surface [126].   
Biological functions of HSPGs range from simple mechanical support of mediator proteins to 
more articulate effects on cell proliferation and differentiation (Figure 1.4). They facilitate 
angiogenesis by potentiating receptor binding and signaling of e. g. VEGF165, basic FGF 
(bFGF), and PDGF-B [127]. HS forms ternary complexes with growth factors and receptors, as 
shown for VEGF165 and bFGF. Furthermore, HS on the cell surface binds growth factors, thus 
forming concentration gradients, while HS in the ECM sequester these mediators, thereby 
protecting them from proteolysis and increasing their thermal stability [127]. Contrary to this, 
angiogenesis can be blocked by interaction of free forms of HSPGs and Hep with growth 
factors, thus hampering their interaction with pro-angiogenic receptors and subsequently the 
activation of EC [128]. Induction and inhibition of angiogenesis are of great clinical interest as 
a means to stimulate tissue repair (e.g. in diabetic ulcers) or to inhibit excessive vessel 
development (e.g. in tumor progression). HS has already been used as a therapeutic target to 
inhibit angiogenesis by disrupting HSPG/growth factor interaction using soluble competitors 
[129] or by reduction of HS expression and specific sulfation [127]. 
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Figure 1.4. Schematic overview of pro- and anti-angiogenic effects of HSPGs/GAGs exerted via pro-
angiogenic growth factors and their receptors. AGF: angiogenic growth factor. 
 
1.3.2.1 VEGF and GAGs in angiogenesis 
 
The VEGF family of cytokines is composed of five structurally related factors: VEGF-A, VEGF-
B, VEGF-C, VEGF-D and placenta growth factor [130]. VEGF-A, the prototype member, is a 
45 kDa homodimeric glycoprotein and the most potent and specific regulator in physiological 
and pathological angiogenesis [131]. It is required for the chemotaxis and differentiation of 
endothelial precursor cells (angioblasts), EC proliferation, the direct assembly of ECs into 
vascular structures (vasculogenesis) and angiogenic remodeling [121]. Loss of a single VEGF-
A allele results in abnormal blood vessel development and embryonal death, highlighting its 
importance in vascular development [132,133]. Several mechanisms tightly regulate the 
cellular responses to VEGF, including expression of different members of this family, 
expression of alternatively spliced variants, and ligand binding to different receptors [121]. 
Alternative splicing of VEGF-A gives rise to at least eight isoforms (VEGF121, 145, 162, 165, 
183, 189 and 206) [134,135]. They differ in their affinity for VEGF receptors and HSPGs due 
to differences in the exons 6 and 7 of the VEGF-A gene that code for two independent HBDs. 
The balance between the different VEGF-A isoforms can regulate blood-vessel growth and 
patterning [121,136]. VEGF121 is a freely diffusible protein since it is the only isoform without a 
HBD (Figure 1.5) [137]. In contrast, VEGF189 is nearly completely sequestered in the ECM due 
to its high affinity for heparin/HS [138]. VEGF165 - the major gene product found in human 
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tissues - has intermediate properties; it is secreted, but a significant fraction remains bound to 
the cell surface and ECM [135]. The loss of HBD leads to a loss in mitogenic activity of VEGF. 
These findings suggest optimal characteristics regarding VEGF165 bioavailability and biological 
potency [139]. 
 
Figure 1.5. Exon structure and function of three VEGF-A isoforms resulting from alternative splicing. 
Isoforms differ in the expression of the HBD resulting in different property profiles and functions (adapted 
and modified from [135]). 
 
VEGF165 exerts its biological effects through binding to the high affinity receptor tyrosine 
kinases VEGF receptor-1 (VEGFR-1) and -2 (VEGFR-2) as well as to the co-receptor 
neuropilin-1 (NRP-1), all of which are predominantly expressed on ECs [135]. VEGFR-1 and -
2 consist of an extracellular domain (ECD) comprising seven immunoglobulin (Ig)-like domains, 
a transmembrane domain, a cytoplasmic kinase domain that is divided into two parts by 
insertion of a non-catalytic sequence, and a C-terminal tail [122].   
Gene knockout studies have proven both receptors to be essential for the development of the 
vasculature in mouse embryos [140,141], but the major receptor for the mitogenic, angiogenic 
and vascular permeability enhancing effects of VEGF165 is VEGFR-2 [142]. Upon ligand 
binding VEGFR-2 undergoes dimerization and strong autophosphorylation of the 
intracytoplasmic domains in specific tyrosine residues, resulting in a mitogenic, chemotactic 
and prosurvival signal [130,131,142]. VEGFR-1 has higher affinity for VEGF165 than VEGFR-2 
but a weak tyrosine kinase activity and does not transmit a mitogenic signal. It is rather a decoy 
receptor that binds VEGF165 to negatively regulate VEGFR-2 signaling and formation of 
angiogenic sprouting [130,139,143]. Activation of VEGFR-2 initiates intracellular signaling 
pathways, like the phospholipase Cγ (PCγ)-ERK1/2 pathway, the phosphoinositide 3-kinase 
(PI3K)-protein kinase B (AKT)-mechanistic target of rapamycin (mTOR) pathway, SRC and 
small GTPases. In addition to these extensively studied signaling events, other pathways are 
activated that are still poorly understood, including stress kinases (p38 mitogen-activated 
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protein kinases), mitogen-activated protein kinase (MAPK), signal transducers and activators 
of transcription (STATs) and G protein-coupled receptor-dependent signaling [144–146].
  Hep and HS have profound effects on VEGF165 function, not only by binding VEGF165 
directly but also by interaction with VEGF receptors and NRP-1 [147–149]. In vitro cell culture 
experiments and ELISA studies demonstrated the requirement of cell surface HS for binding 
of VEGF165 to VEGFR-2, enhancing VEGF165-induced phosphorylation of VEGFR-2 and 
increasing mitogenic activity as well as endothelial tube formation [150–153]. Furthermore, it 
was shown that binding of VEGF165 to VEGFR-1 depends on cellular HSPGs. Exogenous 
Hep/HS cannot compensate for the loss of cell surface HS, suggesting its role in VEGF165 
presentation [151,154]. Cell culture experiments in conjunction with SPR measurements 
demonstrated that Hep modulates binding of VEGF165 to VEGFR-2 depending on the size of 
the Hep species, on its level of sulfation, sugar ring stereochemistry and conformation [155–
157]. Further SPR binding studies and in vitro binding assays showed that Hep binds only 
weakly to NRP-1 alone but revealed a synergistic interaction in the presence of also VEGF165 
and VEGFR-2 [158]. 
 
1.3.2.2 bFGF and GAGs in angiogenesis 
 
bFGF was the first pro-angiogenic molecule to be identified [159]. It belongs to a family of 23 
structurally related polypeptides that play an important role in the control of embryogenesis, 
cell growth and differentiation [160–162]. bFGF is a potent mitogen for a variety of cells, 
including fibroblasts, smooth-muscle cells and vascular ECs [163,164]. In contrast to VEGF, 
FGFs lack a classical signaling sequence and are therefore not secreted but rather remain cell-
associated unless released through cell injury or death [165]. Extracellular bFGF is generally 
immobilized to the cell surface and the ECM and not found in significant amounts as a free 
molecule in serum [166–171]. 
 FGFs exert their biological effects through binding to high affinity tyrosine kinase FGF 
receptors (FGFRs) on the surface of target cells [172]. Alternative splicing of the FGFR mRNA 
generates receptor variants [173,174] displaying a range of receptor-ligand interactions [175]. 
In vitro, ECs express FGFR1 and, under some circumstances FGFR2, while the expression of 
FGFR3 and 4 has never been reported [176–178]. Activation of FGFR1 by angiogenic bFGF 
leads to EC proliferation [122], involving the activation of several parallel signaling pathways. 
Besides activation of the MAPK signaling pathway, a long-lasting activation of protein kinase 
C (PKC) is required for bFGF to exert a full mitogenic response to ECs [179]. FGFR1 is required 
for the development and maintenance of vasculature in the embryo, as shown in experiments 
using adenovirus-mediated expression of dominant-negative FGFR1 in mouse embryos [180]. 
Inactivation of the gene encoding for bFGF, in contrast, results in morphologically normal mice 
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that display decreased vascular tone and low blood pressure [181]. This suggests redundancy 
in the FGF family.   
bFGF interacts with Hep and HS attached to HSPGs. In addition to a canonical Hep-binding 
site, bFGF has two secondary sites as well. Although the affinities of the latter are modest they 
are functionally important, as a deletion of the binding sites causes a small but significant 
reduction of bFGF mitogenic activity [182]. The importance of bFGF/Hep interaction has been 
demonstrated by the observation that Hep protects bFGF from enzymatic degradation and 
denaturation [183,184].   
It was shown that the biological activity of bFGF is modulated by Hep, depending on its size 
and degree of sulfation [185–187]; effects exerted by the HS/Hep system on FGF biology are 
schematically represented in Figure 1.6. In general, FGFs can be sequestered in the 
extracellular environment by free Hep/HSPGs that can act as antagonists for binding to 
FGFRs. They can form a reservoir of biologically active bFGF that becomes available to target 
cells after enzymatic mobilization [188–190]. Furthermore, HSPGs promote FGF 
internalization, are required for a correct presentation of FGF to FGFRs, leading to the 
formation of HSPG:FGF:FGFR ternary complexes [126,191–194] and can directly activate a 
signal transduction pathway upon binding of FGF [195]. Formation of the complexes effectively 
reduces the concentration of bFGF required to initiate signaling and extends the duration of 
response exerted via its FGFRs [196]. Finally, ECM-associated HSPGs act as a bFGF 
reservoir, leading to higher local concentrations and sustaining the long-term stimulation of 
ECs [197]. 
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Figure 1.6. Biological consequences of the FGF/HSPG interaction. (1) FGF bound to free Hep/HSPG is 
sequestered in the extracellular environment. (2) FGF binds to HSPGs on the EC surface, increasing its 
local concentration. (3) HSPGs promote FGF oligomerization, triggering FGFRs dimerization and (4) 
signal transduction. (5) FGFR signal transduction can also be activated by direct FGF/HSPG interaction. 
(6) HSPG mediate cell internalization of FGF and (7) HSPGs of the ECM act as reservoir for FGF 
(adapted and modified from [172]). 
 
By binding bFGF, Hep and free HSPGs protect the growth factor from proteolytic degradation 
as well as inactivation by heat or acids [183,198]. Binding of FGF to different HSPGs like 
syndecan, betaglycan and perlecan leads to different biological effects. The HSPG syndecan 
inhibits the mitogenic activity of bFGF, whereas perlecan promotes bFGF-induced cell 
proliferation and angiogenesis [199]. Interestingly, modifications of HSPGs composition can 
regulate the sensitivity of the cell for different FGFs [200]. FGFs themselves can regulate 
HSPG synthesis as well as the production of proteases/glycosidases that induce the 
mobilization of free HSPGs/HS chains by digesting the PG [201]. Degradation of the ECM 
leads to mobilization of entrapped bFGF with subsequent activation of an angiogenic response 
[202]. 
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1.4 GAG derivatives as promising tools for the design of functional biomaterials 
 
Sulfated GAGs offer a promising potential to functionalize biomaterials as the use of isolated 
GAGs instead of PGs excludes an immunological reaction against the protein core of the PG. 
Native GAGs, however, have a limited utility for biomedical applications due to their restricted 
availability, batch-to-batch variability and source-dependent biological activity [203]. In 
addition, the non-template driven nature of the biosynthesis makes it challenging to develop 
techniques to amplify native GAGs [204] and they display heterogeneous structural properties 
regarding their chain length, disaccharide composition, sulfation pattern and degree [19]. 
However, native HA composed of repeating disaccharide units of N-acetylglucosamine 
(GlcNAc) and GlcA linked by alternating β-1→3 and β-1→4 glycosidic bonds is an ideal starting 
material for modifications. It is especially appropriate for biomedical applications due to its non-
immunological properties, the ease of chain manipulation and the good availability by bacterial 
production [205]. Low molecular weight HA can be produced by thermal degradation of native 
HA, derived from Streptococcus. By using sulfating agents with different reactivity and altering 
the polymer-to-SO3 ratio the degree of sulfation of HA can be adjusted to obtain low-sulfated 
HA (sHA1) or high-sulfated HA (sHA3). Native CS, which consists of repeating disaccharide 
units of GlcA linked to N-acetylgalactosamine (GalNAc), and over-sulfated CS (sCS3) are used 
compared to HA to evaluate the influence of the carbohydrate backbone of the GAGs in 
addition to sulfation degree and pattern.   
Chemically modified HA and CS derivatives (Figure 1.7) display defined properties regarding 
their monosaccharide composition as well as sulfation pattern and degree. In terms of including 
GAG derivatives in functional biomaterials, the characterization of the structure-function 
relationship of GAGs in their interaction with growth factors and cells is mandatory. To this end 
they have been studied extensively within the collaborative research consortium (CRC) 
Transregio 67 (TRR67) to investigate their interaction with mediator proteins and cells relevant 
to healing processes in direct interaction studies, as well as in in vitro and in vivo experiments 
[206]. 
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Figure 1.7. Chemical structures of HA and CS derivatives used in the CRC Transregio 67 to study their 
interaction with mediator proteins and cells relevant to healing processes in direct interaction studies, in 
vitro cell culture and animal experiments. 
 
Aim of the TRR67 is the design of functional biomaterials for controlling healing processes in 
bone and skin. Biomaterials including GAG derivatives will allow to tune the interaction of the 
material with relevant mediators and cells to improve healing processes especially in health-
compromised patients. Previous TRR67 studies comprised SPR analyses of the structure-
function relationship of sHA and sCS derivatives in their interaction with members of the TGF-
β superfamily (TGF-β1, BMP-2, BMP-4) that play an important role in bone and skin 
regeneration. Further targets have been osteoprotegerin (OPG) and sclerostin, which are 
regulatory proteins of bone formation and remodeling, and TIMP-3, which is an inhibitor of 
MMPs and thereby an important modulator of wound healing. These studies revealed that the 
binding strength depends on the sulfation degree and pattern as well as the composition of the 
carbohydrate backbone of the GAGs [117,207–210]. In case of TGF-β1, BMP-2 and sclerostin 
sHA derivatives demonstrated a higher binding strength than sCS derivatives with comparable 
degree of sulfation.  
To gain further insight into the biological consequences of GAG/mediator protein interactions, 
native interaction partners for the investigated mediator proteins like growth factors receptors 
or solute proteins have been included in SPR interaction studies. For the human BMP-2 
receptor-IA (BMPR-IA) a concentration- and sulfation-dependent decrease of binding strength 
for pre-formed BMP-2/sHA complexes was demonstrated by SPR and supported by 
computational analysis [207]. The latter revealed the highly flexible BMP-2 N-termini to be 
responsible for GAG binding. Their conformational plasticity plays a key role in the structure 
and thermodynamics of the BMP-2/GAG/BMPR-IA system. Results from binding studies and 
computational analysis explain findings from cell culture experiments suggesting that GAGs 
impair BMP-2 receptor binding and subsequently BMP-2 bioactivity as found in the presence 
of Hep by Kanzaki et al. [211].  
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In another study sulfated GAG derivatives were shown to alter the interaction of OPG with 
receptor activator NF-кB ligand (RANKL). SPR and molecular modeling revealed a reduced 
binding of OPG to RANKL in the presence of sulfated GAGs due to a potential GAG binding 
site at the RANKL/OPG interface, hindering the ligand-receptor interaction by electrostatic 
repulsion between GAGs and a negatively charged region in RANKL [208]. In line with these 
findings, cell culture experiments demonstrated a sulfate- and dose-dependent loss of OPG 
bioactivity and rescued osteoclast formation in an in vitro osteoclastogenesis model.  
GAG derivatives also interact with TIMP-3 in a sulfation-dependent manner without interfering 
with its inhibitory effects on MMPs. However, the TIMP-3/GAG interaction – dependent on GAG 
sulfation - inhibited the binding of TIMP-3 to low-density lipoprotein receptor related protein-1 
(LRP-1) cluster II and IV, which mediates the up-take and degradation of TIMP-3 from the 
extracellular environment [212].  
Sclerostin-GAG interaction was shown to inhibit the complex formation of sclerostin with its co-
receptor low-density lipoprotein receptor-related protein 5/6 (LRP5/6) in a dose- and sulfation-
dependent manner [213]. As sclerostin is an inhibitor of Wnt signaling, this rescued Wnt 
signaling in vitro.  
The influence of GAG derivatives on functions and pathways of healing-relevant cell types was 
further studied with solute GAGs in a solute form or incorporated in artificial ECMs (aECMs) 
based on collagen type I that mimic the native ECM. These aECMs were shown to exert anti-
inflammatory and immunomodulatory properties towards macrophages and dendritic cells 
[214,215]. Regarding cells involved in wound healing, the adhesion and proliferation of 
fibroblasts on aECMs was enhanced in a sulfation-dependent manner while the synthesis of 
collagen and HA and the expression of MMP-1 was decreased on aECMs containing sHA3 
and sCS3 [216]. In addition, sHA3 alone and sHA3 containing aECMs inhibited the 
differentiation of fibroblasts to myofibroblasts due to reduced TGF-β1 bioactivity [118]. For 
bone cells, sHA containing aECMs were shown to enhance osteogenic differentiation of human 
mesenchymal stromal cells (hMSCs) [217,218], and solute sHA3 caused a reduced osteoclast 
differentiation and resorption [208,219]. 
Furthermore, the potential of GAG-containing aECMs for improved healing processes was 
investigated in vivo. In the minipig mandible aECM coatings of dental implants supported peri-
implant bone formation and increased bone volume density compared to the uncoated control 
[220]. In the maxilla, coatings with collagen/sHA1 increased the bone implant contact [221]. 
Inflammatory or foreign body reactions were not observed in these studies. Findings revealed 
a certain potential of aECM coatings to influence osseointegration in dental applications.  
Studies with titanium-coated polyetheretherketone (Ti-PEEK) plates coated with aECMs and 
implanted in critical size defects in the rat femur showed a significantly reduced gap size for 
collagen/sHA3 and collagen/CS coatings, which induced the highest amount of newly formed 
bone [222].  
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In another animal experiment, macroporous thermopolymerized lactide-based scaffolds 
coated with aECMs were inserted into subcritical size femoral defects in non-diabetic and 
diabetic ZDF rats. In diabetic rats an accelerated bone defect regeneration was observed for 
collagen/HA and collagen/sHA3 coatings compared to the non-coated controls, while this effect 
was not apparent in non-diabetic rats [223]. Collagen/sHA3 promoted bone mineralization and 
decreased the amount of non-mineralized bone matrix and collagen/sHA3-coated scaffolds 
from diabetic rats bound more sclerostin in vivo than the respective controls. Hence aECMs 
appear to enhance bone regeneration in critical size defects and under diabetic conditions, and 
the results achieved so far clearly show that GAG derivatives added to the cell culture medium 
or as part of collagen-based aECMs influence functions and pathways of healing relevant 
mediators and cell types in vitro and in vivo. 
 
1.5 Objective 
 
The present thesis was conducted within the scope of the TRR67 “Functional biomaterials for 
controlling healing processes in bone and skin – from material to clinics”. Based on the previous 
in vitro and in vivo findings on GAG derivatives which revealed promoting effects on bone 
formation and wound healing, the goal of the present study was to gain deeper insights into 
the GAGs’ mode of action in affecting cellular processes. Direct and indirect effects were 
studied, including growth factor independent action of GAGs as well as interaction with growth 
factors and subsequent modulation of their biological activity profiles. In this respect the focus 
was on TGF-β1 and the angiogenic growth factors VEGF165 and bFGF.  
The specific aims of the thesis were as follows: 
1. Characterization of the structure-function relationship of sulfated GAG derivatives by 
▪ Studying their direct interaction with growth factors 
▪ Examining the binding profiles of GAG-bound growth factors with their native 
signaling receptors 
This was achieved using SPR and ELISA. Direct interactions of GAG derivatives with VEGF165 
and bFGF were studied for the first time. For TGF-β1 the molecular mechanism of the GAGs’ 
impact on the complex TGF-β1:receptor interplay was investigated to explain effects on TGF-
β1 bioactivity observed in previous cell culture experiments. 
2. In vitro evaluation of the biological consequences of growth factor/GAG interaction on cells 
relevant to wound healing by 
▪ Studying the activation of growth factor receptors (TβR-I and VEGFR-2) in a 2D cell 
culture assay using fibroblasts and endothelial cells 
▪ Employing a 3D in vitro angiogenesis assay 
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3. Assessing growth factor-independent effects of GAG derivatives to identify potential 
alternative targets for their influence on cellular processes 
The hypotheses of this thesis are that: 
▪ GAG derivatives bind to the growth factors and consequently modulate their biological 
activity profile selectively, depending on the carbohydrate backbone as well as the sulfation 
degree and pattern 
▪ The growth factor/GAG interaction modulates the biological activity of the growth factors 
▪ The order of binding events in the interplay of GAGs, growth factors and signaling receptors 
has an impact on the GAGs’ effect on the biological activity of growth factors 
▪ GAG derivatives exert direct effects on cellular processes, which might be contrary to 
growth factor-dependent actions 
These studies contribute to a deeper understanding of the growth factor/GAG interaction and 
its biological outcome in vitro and in vivo. Analyzing the structure-function relationship of GAGs 
in their interaction with growth factors is a prerequisite for the design of aECMs composed of 
collagen I and GAG derivatives, as such cell instructive microenvironments need complex 
interaction profiles to selectively influence and improve healing processes in skin and bone. 
Especially in health-compromised patients this could potentially improve the life quality of 
patients and decrease health care costs.
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Equipment 
 
Accu-jet pipette aid Brand GmbH, Wertheim, Germany 
Axiovert 40 CFL microscope Carl Zeiss, Jena, Germany 
Bench Biowizard KOJAIR, Vilppula, Finland 
Biacore T100 GE Healthcare, Freiburg, Germany 
Blotting chamber Fastblot B44 Biometra GmbH, Göttingen, Germany 
Camera AxioCam ERc 5s Carl Zeiss, Jena, Germany 
CCD camera system MF-ChemiBIS1.6 Biostep, Burkhardtsdorf, Germany 
Centrifuges 
Centrifuge 5702 R 
Centrifuge 5415 D 
Sigma 3K30 
 
Eppendorf AG, Hamburg, Germany 
Eppendorf AG, Hamburg, Germany 
Sigma Laborzentrifugen GmbH, Osterode am 
Harz, Germany  
CO2 incubator Sanyo Electric Co., Ltd., Moriguchi, Japan 
Cryo freezing container (Mr. Frosty) VWR International GmbH, Darmstadt, 
Germany 
Eve® automated cell counter VWR International GmbH, Darmstadt, 
Germany 
Gel drying frame Carl Roth, Karlsruhe, Germany 
Gel electrophoresis chamber EasyPhor 
PAGE Mini Wide System 
Biozym Scientific GmbH, Hessisch Oldendorf, 
Germany 
Gel electrophoresis chamber SE600 Hoefer, MA, USA 
Multichannel pipette (8 and 12 channels) Eppendorf AG, Hamburg, Germany 
Multistep pipette Brand GmbH, Wertheim, Germany 
Orbital shaker Unimax 2010 Heidolph, Schwabach, Germany 
Pipettes Eppendorf AG, Hamburg, Germany 
Refrigerated circulator FE25-HE JULABO GmbH, Seelbach, Germany 
Tecan Infinite M200 Pro Tecan Group, Männedorf, Schweiz 
Vacuum pump AA Carl Roth, Karlsruhe, Germany 
Vortex genie 2 Scientific Industries, New York, USA 
Water bath JULABO GmbH, Seelbach, Germany 
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2.1.2 Consumables 
 
96-well microtiter plates (flat bottom, 
adhesive) 
Sarstedt AG, Nümbrecht, Germany 
96-well microtiter plates (flat bottom, 
black) 
Fisher Scientific, Schwerte, Germany 
96-well plates (round bottom, non-
adhesive) 
Greiner Bio-One, Frickenhausen, Germany 
Beakers, glassware Schott AG, Mainz, Germany 
VWR, Darmstadt, Germany 
Cellstar® tubes (15 ml, 50 ml) Greiner Bio-One, Frickenhausen, Germany 
Cell culture flasks (75 cm2, 175 cm2) Sarstedt AG, Nümbrecht, Germany 
Cell scraper Sarstedt AG, Nümbrecht, Germany 
Cellophan sheets Carl Roth, Karlsruhe, Germany 
Filter/Chromatography paper Whatman, Dassel, Germany 
Filter pipette tips (1250, 100, 10 µl) Sarstedt AG, Nümbrecht, Germany 
Glass flasks  
(50, 100, 250, 500, 1000, 2000 ml) 
Schott AG, Mainz, Germany 
Graduated flasks  
(50, 100, 200, 250, 500 ml) 
Hirschmann Laborgeräte GmbH, Eberstadt, 
Germany 
Low binding filter pipette tips (10, 300 µl) Greiner Bio-One, Frickenhausen, Germany 
Low binding filter pipette tips  
(100, 1250 µl) 
Sarstedt AG, Nümbrecht, Germany 
Low binding micro centrifuge tubes  
(0.65 ml) 
Carl Roth, Karlsruhe, Germany 
Low binding micro centrifuge tubes  
(1.7 ml, 2.0 ml) 
Sarstedt AG, Nümbrecht, Germany 
Low binding 5 ml centrifuge tubes  VWR, Darmstadt, Germany 
Micro centrifuge tubes (1.7 ml, 2.0 ml) Sarstedt AG, Nümbrecht, Germany 
Nitrocellulose membrane GE Healthcare, Freiburg, Germany 
Nunc 48-well plates Fisher Scientific, Schwerte, Germany 
Nunc MaxiSorp® 96-well microtiter plates Fisher Scientific, Schwerte, Germany 
Pasteur capillary pipettes  
(150 mm, 230 mm) 
Carl Roth, Karlsruhe, Germany 
Pipette tips (10, 200, 1000, 5000 µl) Greiner Bio-One, Frickenhausen, Germany 
Plastic vials (7 mm, 11 mm, 15 mm) GE Healthcare, Freiburg, Germany 
Rubber caps (type 2, type 3) GE Healthcare, Freiburg, Germany 
Series S sensor chips (C1, CM3) GE Healthcare, Freiburg, Germany 
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Serological pipettes  
(2 ml, 5 ml, 10 ml, 25 ml)  
Corning, Amsterdam, The Netherlands 
Single-use syringes Henke-Sass Wolf GmbH, Tuttlingen, Germany 
Syringe filters, 0.2 µm pore size Sarstedt AG, Nümbrecht, Germany 
TPP 6-well tissue culture plates Dr. Ilona Schubert Laborfachhandel, Leipzig, 
Germany 
Vacuum filter/storage bottle system,  
0.22µm Pore 
Corning, Amsterdam, The Netherlands 
 
 
2.1.3 Chemicals, reagents and kits 
 
1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) 
Sigma-Aldrich, Taufkirchen, Germany 
3,3',5,5'-Tetramethylbenzidine (TMB) Sigma-Aldrich, Taufkirchen, Germany 
Acetat buffer, 10 mM, pH 4.5, 5.0, 5.5 GE Healthcare, Freiburg, Germany 
Acetic acid Sigma-Aldrich, Taufkirchen, Germany 
Acrylamide/bis-acrylamide (30%) Carl Roth, Karlsruhe, Germany 
Ammonium persulfate (APS) Carl Roth, Karlsruhe, Germany 
Aprotinin Sigma-Aldrich, Taufkirchen, Germany 
Ascorbic acid PromoCell, Heidelberg, Germany 
Biotinylated protein ladder Cell Signaling Technology, Leiden, The 
Netherlands 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Bromophenol blue SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
Collagen type I, rat tail Corning, Amsterdam, The Netherlands 
Disodium hydrogen phosphate 
(Na2HPO4) 
Carl Roth, Karlsruhe, Germany 
Dithiothreitol (DTT) Fisher Scientific, Schwerte, Germany 
Dry milk Sigma-Aldrich, Taufkirchen, Germany 
Dulbecco’s Modified Eagle’s Medium Biochrom AG, Berlin, Germany 
DuoSet IC human phospho-VEGF 
R2/KDR 
Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
DuoSet IC human total VEGF R2/KDR Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
Endothelial basal medium (EBM) 2  PromoCell, Heidelberg, Germany 
Ethylendiaminetetraacetic acid (EDTA) Sigma-Aldrich, Taufkirchen, Germany 
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Ethanol TU Dresden, Dresden, Germany 
Ethanolamine-HCl Sigma-Aldrich, Taufkirchen, Germany 
Fetal bovine serum Biochrom AG, Berlin, Germany 
Fetal calf serum PromoCell, Heidelberg, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
Glycine Sigma-Aldrich, Taufkirchen, Germany 
Heparin PromoCell, Heidelberg, Germany 
Hydrochloric acid (HCl) Sigma-Aldrich, Taufkirchen, Germany 
Hydrocortisone PromoCell, Heidelberg, Germany 
N-2-Hydroxyethylpiperazine-N’-2-
ethanesulfonic acid (HEPES) 
Sigma-Aldrich, Taufkirchen, Germany 
Immobilon Western Chemiluminescent 
HRP Substrate 
Merck, Darmstadt, Germany 
Isopropanol Merck, Darmstadt, Germany 
LDH cytotoxicity detection kit Takara, Saint-Germain-en-Laye, France 
L-glutamine Biochrom AG, Berlin, Germany 
Medium 199 (10x) Sigma-Aldrich, Taufkirchen, Germany 
Methanol VWR International GmbH, Darmstadt, 
Germany 
Methyl cellulose Sigma-Aldrich, Taufkirchen, Germany 
Neutravidin Fisher Scientific, Schwerte, Germany 
N-Hydroxysuccinimide Sigma-Aldrich, Taufkirchen, Germany 
N,N,N’,N’-Tetramethylethylenediamine 
(TEMED) 
Carl Roth, Karlsruhe, Germany 
Nonidet P-40 Sigma-Aldrich, Taufkirchen, Germany 
Nonidet P-40 Alternative Merck, Darmstadt, Germany 
Phenylmethylsulfonyl fluoride (PMSF) AppliChem GmbH, Gattersleben, Germany 
Penicillin/streptomycin Biochrom AG, Berlin, Germany 
Ponceau S solution AppliChem GmbH, Gattersleben, Germany 
Potassium chloride (KCl) Sigma-Aldrich, Taufkirchen, Germany 
Potassium dihydrogen phosphate 
(KH2PO4) 
Merck, Darmstadt, Germany 
Prestained protein ladder  
(PageRuler Plus) 
Fisher Scientific, Schwerte, Germany 
PrestoBlue® cell viability reagent Fisher Scientific, Schwerte, Germany 
Roti®-Quant (protein quantification) Carl Roth, Karlsruhe, Germany 
Silver stain kit Fisher Scientific, Schwerte, Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
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Sodium azide (NaN3) Sigma-Aldrich, Taufkirchen, Germany 
Sodium bicarbonate Biochrom AG, Berlin, Germany 
Sodium fluoride (NaF) Sigma-Aldrich, Taufkirchen, Germany 
Sodium hydroxide (NaOH) Carl Roth, Karlsruhe, Germany 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich, Taufkirchen, Germany 
Sodium pyruvate Biochrom AG, Berlin, Germany 
Streptavidin-horseradish peroxidase 
(HRP) 
Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
Stripping Buffer Thermo Fisher Scientific, Darmstadt, Germany 
Sucrose Sigma-Aldrich, Taufkirchen, Germany 
Sulfuric acid Sigma-Aldrich, Taufkirchen, Germany 
Surfactant P20 GE Healthcare, Freiburg, Germany 
Tris Sigma-Aldrich, Taufkirchen, Germany 
Triton X-100 Sigma-Aldrich, Taufkirchen, Germany 
Trypsin Sigma-Aldrich, Taufkirchen, Germany 
Trypsin-EDTA Biochrom AG, Berlin, Germany 
Tween® 20 Sigma-Aldrich, Taufkirchen, Germany 
Ultrapure water Merck, Darmstadt, Germany 
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2.1.4 GAG derivatives 
Sample DS a Mw [g/mol] b 
Sulfate group 
distribution 
Supplier 
HA - 48.255 - 
Biomaterials Department, 
Innovent 
 e.V. Jena, Germany 
sHA1 1.0 26.610 6 
Biomaterials Department, 
Innovent e.V. Jena, Germany 
sHA2 1.8 29.040 462’, 463’ 
Biomaterials Department, 
Innovent e.V. Jena, Germany 
sHA3 2.9 20 950 462’, 463’, 62’3’ 
Biomaterials Department, 
Innovent e.V. Jena, Germany 
CS 0.8 20,600 4,6 
Biomaterials Department, 
Innovent e.V. Jena, Germany 
sCS3 3.1 19,900 462’, 463’, 62’3’ 
Biomaterials Department, 
Innovent e.V. Jena, Germany 
Hep 2.2 18,000 62’, 2N, 6 
Sigma-Aldrich, Taufkirchen, 
Germany 
HA dp4 - 777 - 
Institute of Pharmacy, Freie 
Universität Berlin, Germany 
sHA1 dp4 1.0 1005 6 
Institute of Pharmacy, Freie 
Universität Berlin, Germany 
sHA2Δ6s dp4 2.0 1355 2’3’ 
Institute of Pharmacy, Freie 
Universität Berlin, Germany 
psHA dp4 4.0 1763 462’3’ 
Institute of Pharmacy, Freie 
Universität Berlin, Germany 
psHA dp6 4.0 2573 462’3’ 
Institute of Pharmacy, Freie 
Universität Berlin, Germany 
Hep dp6 2.0 1800 62’, 2N Iduron, Manchester, UK. 
aDS: degree of sulfation, average number of sulfate groups per disaccharide unit of GAG 
determined by elemental analysis. bMw: weight-average molecular weight determined by gel 
permeation chromatography. 
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2.1.5 Proteins  
 
2.1.5.1 Proteins for growth factor/GAG interaction studies 
 
Basic fibroblast growth factor (bFGF) Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
Fibroblast growth factor (FGF)  
receptor 1αIIIc (FGFR1αIIIc) 
Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
Transforming growth factor-β1 (TGF-β1) Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
TGF-β receptor I/Fc Chimera Hölzel Diagnostika, Köln, Germany 
TGF-β receptor II/Fc Chimera Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
Vascular endothelial growth factor 
(VEGF)165 
Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
VEGF receptor 2/Fc chimera Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
 
2.1.5.2 Proteins for HUVEC cell culture 
 
bFGF, recombinant human (rhbFGF) PromoCell, Heidelberg, Germany 
Epidermal growth factor, recombinant 
human (rhEGF) 
PromoCell, Heidelberg, Germany 
Insulin-like growth factor (long R3 IGF-1) PromoCell, Heidelberg, Germany 
VEGF165, recombinant human (rhVEGF165) PromoCell, Heidelberg, Germany 
 
2.1.6 Antibodies 
 
Anti-GAPDH mouse monoclonal AB (mAB), 
IgG, CB1001 
Merck, Darmstadt, Germany 
FGF R1 antibody, mouse mAB, IgG, NBP2-
12308 
Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
HRP-conjugated anti-mouse-IgG antibody 
(AB), 7076 
Cell Signaling Technology, Leiden, The 
Netherlands 
HRP-conjugated anti-rabbit-IgG AB, 7074 Cell Signaling Technology, Leiden, The 
Netherlands 
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Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) rabbit polyclonal AB (pAB), 
IgG, 9101  
Cell Signaling Technology, Leiden, The 
Netherlands 
Phospho-Smad2 (Ser465/467) rabbit pAB, 
IgG, 3101 
Cell Signaling Technology, Leiden, 
Netherlands 
TGF beta Receptor I rabbit pAB, IgG, PA5-
14959 
Fisher Scientific, Schwerte, Germany 
TGF beta Receptor I (Phospho-Ser165) 
rabbit pAB, IgG, MBS859620 
BIOZOL Diagnostica Vertrieb GmbH, 
Eching, Germany  
VEGF- Capture antibody, mouse mAB, IgG, 
MAB293 
Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
VEGF165 - Detection antibody goat pAB, 
IgG, BAF293 
Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
VEGF R2/KDR/Flk-1 antibody, mouse mAB, 
IgG, MAB3572-100 
Bio-Techne, Wiesbaden-Nordenstadt, 
Germany 
 
2.1.7 Buffers and solutions 
 
Blocking buffer (VEGFR-2 ELISA) 1% (w/v) BSA 
0.05% (w/v) NaN3 
in PBS 
 
Blocking buffer (Western Blot) 5% (w/v) BSA 
in 25 mM TBST 
 
Blocking solution (SPR) 1% (w/v) BSA 
5% (w/v) sucrose 
in HBS-EP 
 
HBS-EP 10 mM HEPES 
150 mM NaCl 
3 mM EDTA 
0,05% (v/v) Surfactant P20 
in ultrapure water 
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IC Diluent #12 (VEGFR-2 ELISA) 1% (v/v) NP-40 Alternative 
20 mM Tris, pH 8.0 
137 mM NaCl 
10% (v/v) glycerol 
2 mM EDTA 
1 mM activated Na3VO4 
in ddH2O 
 
IC Diluent #14 (VEGFR-2 ELISA) 20 mM Tris, pH 8.0 
137 mM NaCl 
0.05% (v/v) Tween® 20 
0.1% (w/v) BSA 
in ddH2O 
 
Lämmli sample buffer (6x) 0.01% (w/v) bromophenol blue 
30% (v/v) glycerol 
0.3 M Tris-HCl, pH 6.8 
8% (v/v) SDS 
1/10 1 M DTT freshly added before use 
 
Lysis buffer (VEGFR-2 ELISA) 1% (v/v) NP-40 Alternative 
20 mM Tris, pH 8.0 
137 mM NaCl 
10% (v/v) glycerol 
2 mM EDTA 
1 mM activated Na3VO4 
10 µg/ml aprotinin 
10 µg/ml leupeptin 
in ultrapure water 
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Lysis buffer (Western Blot) 50 mM Tris-HCl, pH 7.4 
150 mM NaCl 
1% (v/v) NP-40 
1 mM EDTA 
0.1% (v/v) SDS 
2 mM PMSF 
0.1 mM aprotinin 
0.1 mM Na3VO4 
5 mM NaF 
in ddH2O 
 
Methocel stock solution 2.4 g methyl cellulose (autoclaved) 
add 100 ml EBM 2 (60 °C) incl. 2% 
penicillin/streptomycin 
stirred at RT 
add 100 ml EBM 
stirred at 4 °C overnight 
centrifugation (2h, 2500 x g, RT) 
supernatant stored at 4 °C 
 
Phosphate-buffered saline (PBS) 136.9 mM NaCl 
2.7 mM KCl 
10.1 mM Na2HPO4 
1.7 mM KH2PO4 
 
Resolving gel 12% For 15 ml: 
7.5 ml acrylamide solution 
3.6 ml ddH2O 
3.75 ml resolving gel buffer 
75 µl 20% (v/v) SDS 
75 µl 10% (v/v) APS 
7.5 µl TEMED 
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Resolving gel 15% For 20 ml: 
7.2 ml acrylamide solution 
6.2 ml ddH2O 
2.2 ml resolving gel buffer 
88 µl 20% (v/v) SDS 
88 µl 10% (v/v) APS 
8.8 µl TEMED 
 
Resolving gel buffer  1.5 M Tris 
in ddH2O 
pH adjusted to 8.8 with HCl 
 
Running buffer (SDS-PAGE) 25 mM Tris 
192 mM glycine 
0.1% (v/v) SDS 
in ddH2O 
 
Stacking gel 4% For 10 ml: 
1.3 ml acrylamide solution 
6.1 ml ddH2O 
2.5 ml stacking gel buffer 
50 µl 20% (v/v) SDS 
50 µl 10% (v/v) APS 
10 µl TEMED 
 
Stacking gel buffer  1 M Tris 
in ddH2O 
pH adjusted to 6.8 with HCl 
 
Tris-buffered saline (TBS) 25 mM Tris pH 8  
150 mM NaCl 
in ddH2O 
 
TBST 25 mM Tris pH 8  
150 mM NaCl 
0.05% (v/v) Tween® 20 
in ddH2O 
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Transfer buffer 10% (v/v) methanol 
10% (v/v) 10x running buffer 
in ddH2O 
 
Washing buffer 0.05% (v/v) Tween® 20 
in PBS 
 
 
2.1.8 Primary cells and cell lines 
 
Hs27 foreskin fibroblast cell line  
(CRL-1634TM) 
ATCC, Wesel, Germany 
Human umbilical vein endothelial cells 
(HUVECs)-c pre-screened 
PromoCell, Heidelberg, Germany 
 
2.2 Methods 
 
2.2.1 Surface plasmon resonance 
 
Surface plasmon resonance (SPR) allows monitoring the interaction of biomolecules in real 
time without the need of labeling the interacting partners. For interaction analysis of growth 
factors with GAGs as well as growth factor/GAG complexes with growth factor receptors, a 
BIACORE T100 instrument (GE Healthcare) was used. In Biacore systems the phenomenon 
of SPR occurs on a thin gold film at an interface of media with different refractive index. The 
media with the high refractive index corresponds to the gold-coated glass slide of the sensor 
chip and the media with the lower refractive index constitutes of the aqueous buffer running 
through the flow cell. Experiments involve the immobilization of one reactant to the sensor chip 
surface and injection of the interaction partner in solution. The SPR sensors measure the 
change in refractive index of the solvent near the surface due to complex formation or 
dissociation (Figure 2.1 left). The response of the interaction is quantified in response units 
(RU) and is directly proportional to the concentration of biomolecules on the surface (Figure 
2.1 right). [224,225]. 
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2.2.2 Immobilization of ligands 
 
Growth factors (VEGF165, bFGF) were immobilized on the surface of a Series S Sensor Chip 
CM3 (gold surface functionalized with a short dextran matrix) at 25°C in HBS-EP running buffer 
using the amine coupling reaction according to the manufacturer’s protocol. The carboxyl 
groups of the dextran matrix were activated to succinimide esters with a freshly prepared 
mixture of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and  
N-hydroxysuccinimide (NHS), which was injected over the flow cell for 7 min at 10 μl/min. 
Subsequently, 5-10 µg/ml growth factor diluted in sodium acetate buffer pH 5.5 were injected 
at 5 µl/min until an immobilization level of approximately 1200 RU was achieved. Remaining 
reactive groups were deactivated with 1 M ethanolamine-HCl pH 8.5 at 10 µl/min for 7 min. As 
a reference one flow cell was activated and directly deactivated without immobilizing one of 
the growth factors. Immobilization of growth factor receptors (TβR-I, TβR-II, VEGFR-2, 
FGFR1IIIc) was performed using Series S Sensor Chips C1 (carboxylated gold surface) at 
25°C in HBS-EP running buffer. Prior to immobilization the C1 Sensor Chip was conditioned 
as recommended by the manufacturer using two pulses of 0.1 M glycine-NaOH, pH 12 for 
60 sec at 10 µl/min. Receptors were diluted in sodium acetate buffer according to Table 2.1 to 
the indicated dilutions. Immobilization occurred according to the procedure described above 
with the injection of receptor protein at 5 µl/min to achieve the average immobilization levels 
shown in Table 2.1. A reference surface was included as well. Prior to interaction analysis, the 
chip surface with immobilized receptors was blocked with three injections of blocking solution 
(3 x 700 s at 30 µl/min). 
Figure 2.1. Surface Plasmon Resonance. Detection principle (left) and a schematic illustration of a 
representative SPR sensorgram (right) adapted and modified from [224]. 
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Table 2.1. Immobilization conditions used for the different growth factor receptors in SPR experiments. 
Growth Factor 
Receptor 
Dilution in sodium 
acetate buffer pH … 
Concentration [µg/ml] Immobilization level [RU] 
TβR-I 5.0 100 130 
TβR-II 4.5 100 200 
VEGFR-2 4.5 50 225 
FGFR1IIIc 4.5 50 100 
 
2.2.3 Interaction studies with solute GAG derivatives 
 
Interaction studies were performed at 37°C in HBS-EP. GAG samples were diluted in HBS-EP 
to 1 µM, 10 µM and 100 µM GAG related to the molecular weight of disaccharide units (D.U.) 
for polymeric GAGs and 10 µM, 100 µM and 500 µM D.U. for oligomeric GAGs. After three 
start up injections with running buffer, GAG dilutions were injected for 300 s at 30 µl/min and 
binding levels were recorded 10 s before injection stop. The injection was followed by a 10 min 
dissociation phase in running buffer at a flow rate of 30 µl/min. The sensor chip surface was 
regenerated after each sample injection with 5 M NaCl in 40 mM NaOH for 60 sec at a flow 
rate of 30 µl/min. The baseline was allowed to stabilize for 1000 s with running buffer prior to 
injection of the next sample. Binding parameters were evaluated using the BIACORE T100 
evaluation software 2.03. Data were double referenced by the response of the reference 
surface and the response of HBS-EP buffer alone relative to a baseline report point. 
Furthermore, binding levels were corrected for the respective molecular weight of the GAG 
derivative to consider the fact that the SPR binding response is related to a mass increase at 
the sensor chip surface.  
2.2.4 Receptor binding studies with solute GAG/growth factor complexes 
 
For interaction studies with the receptors different concentrations of GAG derivatives were pre-
incubated for 60 min at room temperature (RT) with the respective growth factor (TGF-β1, 
VEGF165, bFGF) in HBS-EP (Table 2.2). After three start up injections, pre-formed complexes 
of growth factor and GAG (incubated for 1 h at RT) or growth factor alone were injected for 
120 s at 30 µl/min and binding levels were recorded 10 s before injection stop. As a control, 
the highest GAG concentration without growth factor was injected over the immobilized 
receptor. The injection was followed by a 10 min dissociation phase in running buffer at a flow 
rate of 30 µl/min. The sensor chip surface was regenerated after each sample injection with 
20 mM HCl for 2 min at 5 µl/min. The baseline was allowed to stabilize for 1000 s with running 
buffer prior to injection of the next sample. 
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Table 2.2. Concentrations of interaction partners used in growth factor/GAG-receptor SPR binding 
studies. 
Growth factor 
receptor 
Concentration 
growth factor 
GAG derivatives used Concentration GAG 
derivatives 
TβR-I 120 nM TGF-β1 
HA, sHA1, sHA2, sHA3, HA 
dp4, psHA dp4 
100 nM D.U. 
TβR-II 40 nM TGF-β1 
HA, sHA1, sHA2, sHA3, HA 
dp4, psHA dp4 
2 µM D.U., 20 µM D.U. 
VEGFR-2 20 nM VEGF165 
HA, CS, sHA1 2-200 µM D.U. 
Hep, sCS3, sHA3 0.02-20 µM D.U. 
HA dp4, psHA dp4, Hep dp6 0.2-200 µM D.U. 
FGFR1IIIc 40 nM bFGF 
HA, CS, sHA1, Hep, sCS3, 
sHA3, HA dp4, psHA dp4, 
psHA dp6 Hep dp6 
0.2-20 M D.U. 
 
2.2.5 Sequential receptor binding studies with TGF-β receptors 
 
TβR-II was immobilized on a Series S Sensor Chip C1 and three consecutive injections of TGF-
β1, GAG derivative and TβR-I were performed in each running cycle. 40 nM TGF-β1 were 
injected for 120 s at 30 µl/min with a dissociation phase of 30 s in running buffer. Afterwards 
600 µM of the respective GAG derivative were injected under the same conditions followed by 
the injection of 40 nM TβR-I with a dissociation time of 300 s. Additionally, 40 nM TGF-β1 and 
100 µM D.U. of the respective GAG derivative were pre-incubated for 1 h at RT. The pre-formed 
TGF-β1/GAG complexes were injected over immobilized TβR-II, followed by a buffer injection 
and the injection of TβR-I. The sensor chip surface was regenerated after each running cycle 
with a 30 µl pulse of 5 M NaCl in 30 mM NaOH followed by two injections of 20 mM HCl for 
120 s at a flow rate of 5 µl/min. Data were double referenced. 
 
2.2.6 Enzyme-linked immunosorbent assay (ELISA) 
 
2.2.6.1 Biotin-mediated coupling of GAGs to MaxiSorp 96-well plates 
 
Utilizing the strong biotin-neutravidin interaction, MaxiSorp® 96-well microtiter plates were 
coated with biotinylated GAG derivatives. Each well was incubated with 100 µl of a 10 µg/ml 
neutravidin solution in PBS overnight at 4°C. After washing the plates for 3 times with 
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250 µl/well washing buffer 100 µl/well of 2.5 mM D.U. biotinylated GAG were added and 
incubated for 2 h at room temperature. Then wells were washed again (3 x 250 µl/well washing 
buffer) and unspecific binding sites were blocked using 300 µl/well 1% (w/v) BSA /PBS. 
 
2.2.6.2 Sandwich ELISA for interaction of immobilized GAGs with solute growth factors 
 
GAG-coated wells were incubated with 50 µl/well of 0-100 ng/ml VEGF165 in 1% BSA/PBS 
overnight at RT for binding to reach equilibrium. Wells coated with 1% (w/v) BSA and uncoated 
wells served as negative and positive controls, respectively. The binding of VEGF165 to the 
GAG derivatives was determined indirectly using the supernatants in a sandwich ELISA with 
specific VEGF capture and detection antibodies. To this end 100 µl/well of 1 µg/ml VEGF 
capture antibody diluted in PBS were added to a MaxiSorp® 96-well microtiter plate. After 
incubation overnight at 4°C wells were washed three times with 300 µl washing buffer and 
blocked with 300 µl 1% BSA/PBS for 1 h at RT followed by a washing step again (3 x 300 µl/well 
washing buffer). Then 100 µl/well of the supernatants were applied and incubated for 2 h at 
RT. A calibration curve was prepared using VEGF165 concentrations in the range of 0-12.5 
ng/ml in 1% BSA/PBS. After incubation with the supernatants and the standard for calibration 
wells were washed again (3 x 300 µl/well washing buffer). After adding 100 µl/well of 0.1 µg/ml 
VEGF165 detection antibody for 2 h and washing (3 x 300 µl/well washing buffer), wells were 
incubated with 100 µl streptavidin-horseradish peroxidase (HRP) solution (1:200) for 20 min in 
the dark and washed again. 100 µl/well TMB substrate solution were added to the wells for 5-
10 min incubation under exclusion of light. To stop the reaction 50 µl/well 1 M H2SO4 were used 
and absorbance of samples was determined at 450 nm using a TECAN reader. 
 
2.2.6.3 VEGFR-2 ELISA 
  
Activation of VEGFR-2 in HUVEC cells stimulated with VEGF165/GAG complexes was 
determined using two sandwich ELISA kits detecting phosphorylated VEGFR-2 (P-VEGFR-2) 
and total VEGFR-2, respectively, according to the manufacturer’s protocol. Concentrations of 
antibodies and standards used in both ELISAs are summarized in Table 2.3. HUVECs were 
cultivated as described in section 1.3.1.2, trypsinized and seeded in 6-well plates at a density 
of 10,000 cells/cm2 in complete endothelial cell medium for 24 h at 37°C. Prior to stimulation 
HUVECs were serum-starved for 24 h in Endothelial Basal Medium (EBM) containing only 
0.2% FCS, 0.1% BSA and 1% penicillin/streptomycin (Pen/Strep). Cells were treated with pre-
formed complexes of 2.6 nM VEGF165 and 200 µM D.U. GAG (pre-incubated for 10 min at 
37°C) for 10 min. SU1498, a specific VEGFR-2 inhibitor was used as a reference for reduced 
phosphorylation and was added at a concentration of 100 nM. After lysis cell lysates were 
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scraped out of the wells, transferred to micro centrifuge tubes and kept at 4°C for further 
proceeding. After centrifugation (2000 x g, 5 min, 4°C) supernatants were applied to 
MaxiSorp® 96-well microtiter plates that were coated with 100 µl/well VEGFR-2 capture 
antibody in PBS overnight, washed (3 x 300 µl/well washing buffer) and blocked with 300 
µl/well blocking buffer for 1 h at RT. Standards for phosphorylated and total VEGFR-2 diluted 
in IC-Diluent #12, respectively, were included. 100 µl/well cell lysates or standards, 
respectively, were incubated for 2 h followed by an incubation with 100 µl/well detection 
antibody for total VEGFR-2 and an HRP-conjugated anti-phospho tyrosine antibody for P-
VEGFR-2 diluted in IC Diluent #14. After 2 h plates were washed (3 x 300 µl/well washing 
buffer) and samples tested for total VEGFR-2 were incubated with 100 µl/well streptavidin-HRP 
(1:200 in IC Diluent #14) for 20 min and washed afterwards. All samples were incubated with 
100 µl/well TMB substrate solution for 5-15 min in the dark. Reaction was stopped with 50 
µl/well 1M H2SO4 and absorbance was measured using a TECAN reader at 450 nm including 
a wavelength correction at 540 nm. 
Table 2.3. Concentrations of antibodies and standards used in VEGFR-2 ELISAs. 
 P-VEGFR-2 Total VEGFR-2 
Capture antibody 8 µg/ml 4 µg/ml 
Detection antibody 1:1500, HRP-conjugated 0.2 µg/ml 
Standard 0-8000 pg/ml 0-4000  pg/ml 
 
2.2.7 In vitro cell culture 
 
2.2.7.1 Maintenance, conservation and treatment of cells 
 
Hs27 fibroblast cells (ATCC-CRL-1634, human foreskin fibroblast cell line) were maintained in 
complete medium (Dulbecco’s Modified Eagle’s Medium; DMEM) with 10% (v/v) fetal bovine 
serum (FBS), 1.5 g/l NaHCO3, 1% Pen/Strep, 100 mM sodium pyruvate and 4 mM L-glutamine 
at 37°C in a humidified atmosphere with 5% CO2. HUVECs (VEGF pre-screened) were 
maintained in EBM supplemented with 2% (v/v) fetal calf serum (FCS), 1% Pen/Strep, 5 ng/ml 
rhEGF, 10 ng/ml rhbFGF, 20 ng/ml R3 IGF-1, 0.5 ng/ml rhVEGF, 1 µg/ml ascorbic acid, 
22.5 µg/ml heparin and 0.2 µg/ml hydrocortisone at 37°C in a humidified atmosphere with 5% 
CO2. Medium was exchanged every 2-3 days. Cells were grown to a maximal confluence of 
80%. After reaching confluence cells were washed with PBS and detached using trypsin-
EDTA. New cell culture flasks were filled with medium and incubated for 30 min at 37°C prior 
to cell seeding. Passages of Hs27 cells used for experiments were not higher than 25 and for 
HUVECs not higher than 4. For long term storage cells were suspended in cryo-medium 
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containing DMEM or EBM, respectively, supplemented with 20% FBS or FCS and 10% (v/v) 
DMSO, then temperature adjusted using a freezing container and subsequently cryo-
conserved in liquid nitrogen. Frozen cells were thawed in a water bath tempered to 37°C for 
2 min, resuspended in 9 ml media and centrifuged to eliminate the DMSO. Cells were then 
processed directly, or proliferating cells were passaged at least once before use. 
 
2.2.7.2 Cell cytotoxicity assay with GAG derivatives 
 
HUVECs or Hs27 fibroblasts, respectively, were seeded into 48 well plates at a density of 
18,000 cells/cm2 in 500 µl/well of the respective complete media and grown for 24 h. A 
calibration curve with defined cell numbers was seeded as well and incubated for 4 h until cells 
attached to the polystyrene. Cells for calibration of cell number were incubated with 
PrestoBlue® cell viability reagent for 90 min. 100 µl/well of the supernatants were transferred 
to black 96-well microtiter plates to determine the fluorescence intensity which correlates to 
the cell number. Fluorescence was measured at λex = 560 nm and λem = 590 nm using the 
TECAN reader. After 24 h medium of samples was exchanged to treatment medium containing 
130 µM D.U. sHA3 or 220 µM D.U. HA. Cells were allowed to proliferate for 48 h and 
supernatants were collected for determination of lactate dehydrogenase (LDH) activity. 
PrestoBlue® reagent was added to the cells that proliferated for 48 h in the presence of GAGs 
for 90 min to determine their cell number/metabolic activity. Cell necrosis was examined using 
50 µl/well of the cell culture supernatants and adding 50 µl/well of LDH working solution in 96-
well microtiter plates. NAD+ is reduced to NADH/H+ by the LDH-catalyzed conversion of 
lactate to pyruvate. The catalyst diaphorase transfers H/H+ from NADH/H+ to the yellow 
tetrazolium salt, which becomes reduced to a red formazan product. Absorbance of the red 
formazan can be measured at 490 nm. The color intensity correlates with the number of dead 
cells. 
 
2.2.7.3 3D in vitro angiogenesis assay 
 
The 3D in vitro angiogenesis assay is a versatile tool capable of physiologically mimicking 
relevant steps of the angiogenic cascade in vitro with relative robustness and high sensitivity 
[226,227]. The protocol was adapted from PromoCell (Heidelberg, Germany) and Korff et al. 
[228]. Confluent (80%) HUVECs were trypsinized and resuspended in EBM containing 2% FCS 
and 10% (v/v) methocel stock solution. 1000 cells/well were seeded in 96-well round-bottom 
well plates to generate spheroids within 18-24 h at 37°C, 5 % CO2. Spheroids were harvested 
using shortened pipette tips and collected in 50 ml centrifuge tubes. After centrifugation (5 min, 
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1000 x g, RT) supernatants were aspirated. The spheroid sediment was loosened by gently 
scraping the tube over a rough surface. Per 100 spheroids 600 µl warm medium containing 
80% methocel stock solution and 20% FCS were added to the tubes without mixing. Collagen I-
M199 solution was prepared using 3 mg/ml collagen diluted in 10 mM acetic acid. One eighth 
of 10x M199 medium was added to 3 mg/ml collagen I and mixed thoroughly. 0.2 M NaOH was 
used to adjust the pH of the collagen I-M199 solution by drop-wise addition until color of the 
solution changed from yellow to purple. 600 µl of the pH-adjusted collagen I-M199 solution 
were added to 100 spheroids in methocel-FCS medium (1:1) and mixed carefully. 400 µl/well 
of the methocel-collagen solution containing the spheroids was added to 48-well plate and 
incubated at 37°C for 30 min. Each well contained 50 spheroids, which were stimulated 
afterwards according to the respective experiment using EBM containing 0.5% FCS, 1% 
Pen/Strep, 25 ng/ml VEGF or bFGF and 100 µM D.U. GAG. Growth factor and GAGs were 
incubated for 10 min at 37°C to form complexes and then added to the samples. For 
experiments using neutralizing antibodies for growth factor receptors 10 µg/ml anti-VEGFR-2 
antibody or anti-FGFR-1 antibody were used. Spheroids were treated with 100 µl stimulating 
solution per well for 24 h. All components (growth factor, GAG, neutralizing antibody) were 
added as 5x stock of the final concentration according to the final volume of 500 µl in the wells. 
Evaluation of sprouting comprised the measurement of individual sprout length, the calculation 
of the cumulative sprout length and the number of sprouts analyzed using ImageJ. 
 
2.2.8 Protein analyses 
 
2.2.8.1 SDS-PAGE and western blot 
 
For western blot experiments Hs27 fibroblast cells were seeded at a density of 13,000 cells/cm2 
in T75 cell culture flasks, grown to 80% confluency and serum-starved for 24 h. Cells were 
stimulated with 0.4 nM TGF-β1 alone or with mixtures of TGF-β1 and 130 µM D.U. sHA3 (pre-
incubated for 2 h at 4°C) for 5 min, 30 min and 60 min. Then cells were washed with PBS and 
incubated in lysis buffer at 4°C for 10 min. Lysates were scraped out of the wells, transferred 
to micro centrifuge tubes and centrifuged (13,000 x g for 30 min at 4°C). Total protein content 
of lysates was determined via Bradford assay using 2 µl lysate and 200 µl Roti®-Quant solution 
(1:5 dilution in dH2O) in 96-well microtiter plates. Absorbance was measured at 595 nm with a 
wavelength correction at 800 nm and correlated to the amount of protein using a BSA standard 
curve. Equal amounts of protein (20 µg) were subjected to 12% SDS-polyacrylamide gels. 
Electrophoresis was performed at 10 mA/gel for samples running in the stacking gel and 20 
mA/gel in the resolving gel. Afterwards the gel was equilibrated in transfer buffer for 30 min 
and the samples were transferred to nitrocellulose membranes by applying 1 mA/cm2 blot 
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membrane. Blotting efficiency was determined by staining the membrane with Ponceau S for 
5 min. The membranes were blocked with blocking buffer or 5% (w/v) dry milk in TBST at RT 
for 2 h and washed afterwards with TBST for 5 min. The following primary antibodies were 
used: rabbit-anti-human TGF beta Receptor I (Phospho-Ser165) pAB, rabbit-anti-human TGF 
beta Receptor I pAB, rabbit-anti-human phospho-Smad2 (Ser465/467) pAB, rabbit-anti-human 
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) pAB and mouse-anti-human GAPDH mAB. 
All primary antibodies were diluted 1:1000 in TBST containing 5% BSA and incubated with the 
blotting membrane overnight at 4°C. HRP-conjugated anti-rabbit-IgG and anti-mouse-IgG in 
TBST containing 5% dry milk at a dilution of 1:2000 were used as secondary antibodies after 
washing the membrane with TBST (3 x 5 min). Incubation with secondary antibody was 
performed for 2 h at RT. After washing with TBST (3 x 5 min) again, immune complexes were 
detected using Immobilon Western Chemiluminescent HRP substrate according to the 
manufacturer’s protocol and visualized by enhanced chemiluminescence detection using a 
CCD camera system. For re-blotting the membrane was incubated in stripping buffer at RT for 
20 min and the immune steps were repeated starting with dry milk incubation. Band signals 
were evaluated densitometrically using ImageQuantTM 5.1 software. 
 
2.2.8.2 SDS-PAGE and silver staining 
 
For bFGF stability experiments 3 µg/ml (75 ng) bFGF were pre-incubated with 1, 10, 50 and 
100 mg/ml of GAG derivatives in 50 mM Tris-HCl, pH 7.5 for 5 min at 37°C. Afterwards, 600 
ng/ml (15 ng) trypsin were added to the pre-formed bFGF/GAG complexes and samples were 
incubated for 3 h at 37 °C. Then 6x Lämmli sample buffer was added to the samples followed 
by a denaturation step at 95°C for 5 min and a short centrifugation. Samples were applied to 
15% SDS polyacrylamide gels. Gel run was performed at 125 V for 2 h. After the run, gels were 
washed 2 x 5 min in ultrapure water, fixed in 30% (v/v) ethanol/10% (v/v) acetic acid solution 
twice for 15 min and washed again 2 x 5 min in 10% ethanol. For subsequent silver staining a 
silver stain kit was used according to the manufacturer’s protocol. Sensitizer was diluted 1:500 
in ultra-pure water and added to the gel for 1 min. Gel was stained for 30 min with the stain 
working solution (1:50 enhancer with stain). After a brief washing (2 x 20 sec) in ultra-pure 
water the gel was developed with 1:50 enhancer in developer for 2-3 min until appearance of 
bands. Reaction was stopped using 5% acetic acid for 10 min. The gels were dried afterwards 
using a gel drying frame after incubation of the gel in 20% ethanol/10% (v/v) glycerol solution 
for 20 min. All incubation steps were performed under gentle shaking using an orbital shaker. 
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2.2.9 Statistics 
 
All experiments were performed at least in triplicate, if not stated otherwise. Exact number of 
replicates is given in each figure legend. Analysis of data and statistics were performed using 
the program GraphPad Prism 5.0. If not mentioned differently, results are presented as mean 
± standard deviation (SD). For sensorgrams and box plots only one representative experiment 
out of multiple measurements is shown. Statistical significance was evaluated using one-way 
or two-way analysis of variance (ANOVA) with Tukey and Bonferroni posthoc test, respectively, 
to evaluate differences between the groups. P-values < 0.05 were considered statistically 
significant. 
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3 Results 
 
The interaction of chemically modified GAG derivatives with growth factors relevant to wound 
healing, i.e. TGF-β1, VEGF165 and bFGF, has been characterized regarding the structure-
function relationship of GAG derivatives in their interplay with these mediators. Furthermore, 
biological consequences have been evaluated regarding the ability of growth factors to bind 
and activate their relevant signaling receptors as well as to induce cellular functions in the 
presence of GAGs. 
 
3.1 Impact of GAG derivatives on TGF-β1 signaling 
 
TGF-β1 is reported to interact with Hep and high sulfated HS, which contributes to its biological 
activity. This is either by binding to the growth factor or by acting as a co-receptor for TGF-β1 
binding to its receptors [113]. Previous SPR interaction studies demonstrated concentration 
and sulfation-dependent binding of TGF-β1 to chemically sulfated GAG derivatives [117]. 
Among the investigated derivatives sHA3 exhibited the strongest interaction with the growth 
factor. To clarify the consequences of TGF-β1/sHA interaction on TGF-β1 biological activity, 
the ability of TGF-β1 to bind and activate its signaling receptors has been investigated. 
 
3.1.1  Receptor binding 
 
The impact of TGF-β1/sHA interaction on the binding of solute TGF-β1 to immobilized receptor/ 
Fc chimeras (TβR-I or TβR-II) was analyzed in SPR studies. Increasing concentration and 
sulfation of sHA derivatives led to a significantly decreased binding of TGF-β1 to TβR-II 
compared to TGF-β1 in the absence of GAG (Figure 3.1 A). sHA3 showed the most 
pronounced influence of all sHA derivatives studied. Up to concentrations of 20 µM sHA3 D.U. 
the binding of TGF-β1 to TβR-II decreased in a concentration dependent manner. Interestingly, 
the binding strength increased again at concentrations above 20 µM D.U. and ultimately 
reached a plateau at concentrations above 200 µM D.U. (Figure 3.1 B). Furthermore, a change 
in the character of binding curves for TGF-β1 binding to TβR-II was detected in the presence 
of > 20 µM D.U. sHA3. The typical curve shape changed to a linear and monotonously rising 
one. This effect was also observed for TGF-β1 pre-incubated with sHA2 but not with sHA1 and 
HA (Figure 3.1 C-E). 
Results   
45 
 
 
Figure 3.1. Interaction of pre-formed TGF-β1/sHA complexes with immobilized TβR-II/Fc chimera as 
determined by SPR. (A) Relative binding of 40 nM TGF-β1 to TβR-II alone and after pre-incubation with 
2 and 20 µM D.U. of HA, sHA1, sHA2 as well as sHA3. Values represent the mean ± SD of n = 3. One-
way ANOVA: *p < 0.05; ***p < 0.001 vs. HA; ##p < 0.01; ###p < 0.001 vs. TGF-β1 alone. Sensorgrams for 
the binding of 40 nM TGF-β1 to TβR-II in the presence of (B) 100 nM - 400 µM D.U. sHA3, (C) 2 µM and 
20 µM D.U. sHA2, (D) sHA1 and (E) HA. One representative sensorgram out of three independent 
measurements is shown. 
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Binding of TGF-β1 to TβR-I was hampered in the presence of increasing concentration and 
sulfation of GAGs as well (Figure 3.2 A). Here the inhibitory effect was more pronounced 
compared to TGF-β1/TβR-II, since the interaction was completely suppressed in the presence 
of 20 µM D.U. sHA3 (Figure 3.2 B). GAG derivatives alone, however, did not bind to TβRs. 
 
Figure 3.2. Interaction of pre-formed TGF-β1/sHA complexes with immobilized TβR-I/ Fc chimera as 
determined by SPR. (A) Relative binding of 120 nM TGF-β1 to TβR-I alone and after pre-incubation with 
100 nM D.U. of HA, sHA1, sHA2 as well as sHA3. Values represent the mean ± SD of n = 3. One-way 
ANOVA: *p < 0.05; ***p < 0.001 vs. HA; ##p < 0.01; ###p < 0.001 vs. TGF-β1 alone. (B) Sensorgram for 
the binding of 120 nM TGF-β1 to TβR-I in the presence of 10 nM-20 µM D.U. sHA3. One representative 
sensorgram out of three independent measurements is shown. 
 
Besides polymeric sHA derivatives, tetrameric non-modified HA (HA dp4) and tetrameric 
persulfated HA (psHA dp4) were used to determine whether these oligosaccharides are 
sufficient for interference with TGF-β1:receptor complex formation. psHA dp4 inhibited the 
interaction of TGF-β1 with TβRs (Figure 3.3) and similar to polymeric sHA derivatives it showed 
a stronger effect on TGF-β1 binding to TβR-I compared to TβR-II. However, higher 
concentrations of psHA dp4 were necessary to observe an inhibition. In contrast to the 
persulfated tetramer, HA dp4 only slightly inhibited the interaction of TGF-β1 with TβRs but did 
not exhibit a concentration dependent effect. As for polymeric GAGs, tetrameric derivatives 
alone did not bind to TβRs. 
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Figure 3.3. Binding of TGF-β1 to immobilized TβR-II and TβR-I after pre-incubation with tetrameric HA 
derivatives. (A) Relative binding of 40 nM TGF-β1 to TβR-II alone and after pre-incubation with 0.1, 2, 
20 and 200 µM D.U. of HA dp4 and psHA dp4. (B) Relative binding of 120 nM TGF-β1 to TβR-I alone 
and after pre-incubation with 0.1, 2, 20 and 200 µM D.U. of HA dp4 and psHA dp4. Values represent the 
mean ± SD of n = 3. Two-way ANOVA: *p < 0.05; ***p < 0.001 vs. respective treatment; #p < 0.05; ###p 
< 0.001 vs. TGF-β1 alone. 
 
In addition to investigations with single TβRs, the impact of sHA derivatives on the TGF-
β1:receptor complex formation was evaluated, which is described as an ordered-sequential 
process in vivo [95–97,99]. To this end SPR experiments including both TβRs in one measuring 
cycle were performed. TβR-II was immobilized on a C1 sensor chip surface and all the other 
components were injected sequentially in the following order: TGF-β1, GAG and TβR-I (Figure 
3.4 A). In the first injection a distinct binding of TGF-β1 to immobilized TβR-II was observed, 
similar to the results described above. GAG binding to TβR-II/TGF-β1 was not very 
pronounced. However, the recruitment of TβR-I to the complex of TβR-II/TGF-β1/sHA3 was 
significantly enhanced compared to complexes without GAG (TGF-β1, buffer, TβR-I; Figure 
3.4 B and D). An enhanced complex formation was observed in the presence of psHA dp4 as 
well (Figure 3.4 C and E). Recruitment of TβR-I was also enhanced when pre-formed TGF-
β1/sHA3 complexes were injected prior to injection of TβR-I, although the binding of TGF-
β1/sHA3 complexes to TβR-II was lower compared to TGF-β1 alone (Figure 3.4 B). There was 
no enhanced TβR-I recruitment in the presence of both polymeric HA and HA dp4. 
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Figure 3.4. Sequential TGF-β1:receptor complex formation in the presence of different HA derivatives. 
(A) Schematic drawing of the experimental set-up with TβR-II immobilized on a C1 sensor chip and all 
other components injected in the order: 1. TGF-β1, 2. GAG, 3. TβR-I. Sensorgrams show the binding of 
TβR-I to TβR-II/TGF-β1 in the presence of (B) polymeric HA and sHA3 or (C) HA dp4 and psHA dp4. 
One representative experiment out of at least three independent measurements is shown. Binding levels 
for the association of TβR-I to the complex of TβR-II/TGF-β1 including the indicated (D) polymeric or (E) 
tetrameric GAGs were ranked. Values represent the mean ± SD of n = 3. One-way ANOVA: *p < 0.05; 
**p < 0.01 vs. control and HA. 
 
3.1.2 Phosphorylation of TβR-I, Smad2 and Erk1/2 
 
SPR binding experiments described in section 3.1.1 showed an altered TGF-β1:receptor 
complex formation in the presence of sHA3. To determine the consequences of this change on 
the phosphorylation of TβR-I and the second messenger molecules Smad2 and Erk1/2, 
western blot analyses were performed. Fibroblast cells were treated either with TGF-β1 alone 
or pre-formed TGF-β1/GAG complexes. Phosphorylation of TβR-I, Smad2 and Erk1/2 was 
detected using specific antibodies. Cells treated with TGF-β1 alone showed a strong Smad2 
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phosphorylation signal compared to the unstimulated control. Treatment with pre-formed TGF-
β1/sHA3 complexes led to a decrease in TGF-β1-mediated Smad2 phosphorylation at every 
time point investigated, which was significant after 5 min (Figure 3.5 A and B). For TβR-I a 
phosphorylation signal was already detectable in untreated cells, but it was enhanced in the 
presence of TGF-β1. Compared to the total amount of TβR-I, TβR-I phosphorylation was 
distinctly reduced after treatment with TGF-β1/sHA3 complexes, although not significantly in 
comparison to the control (Figure 3.5 A and C). No influence of sHA3 was observed regarding 
the TGF-β1-mediated phosphorylation of Erk1/2 (Figure 3.5 A and D). 
 
 
Figure 3.5. Influence of sHA3 on the TGF-β1-mediated phosphorylation of TβR-I, Smad2 and Erk1/2. 
Hs27 fibroblasts cells were treated with 0.4 nM TGF-β1 alone or with pre-formed complexes of TGF-β1 
and 130 µM D.U. (100 µg/ml) sHA3 for the indicated time points. Cells were lysed and applied to western 
blot analyses using specific anti-TβR-I, anti-phospho-TβR-I, anti-phospho-Smad2, anti-phospho-Erk1/2 
and anti-GAPDH (loading control) antibodies. (A) For every time point a representative blot is shown. 
The time course of TGF-β1-mediated phosphorylation is plotted for (B) Smad2, (C) TβR-I and (D) Erk1/2 
relative to untreated cells. For TβR-I the ratio of phospho-TβR-I/total TβR-I is shown. Values represent 
the mean ± standard error of the mean (SEM) of n = 3. Two-way ANOVA: ***p < 0.001 vs. TGF-β1. 
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3.2 Impact of GAG derivatives on VEGF165 signaling 
 
GAGs, especially HS and Hep, play a key role in the bioavailability of angiogenic growth factors 
like VEGF165, by binding and sequestering them and thereby participating in the formation of 
concentration gradients. They also protect the growth factor from proteolytic degradation 
[229,230], and cell surface HS is reported to be required for binding of VEGF165 to its receptors 
and for its mitogenic activity [149]. To determine the structure-function relationship of 
chemically sulfated GAG derivatives in their interaction with VEGF165, SPR interaction studies 
with polymeric and oligomeric GAGs were performed. The biological consequences of these 
interactions were examined regarding the ability of VEGF165 to bind and activate its primary 
angiogenic signaling receptor VEGFR-2 and to exert its mitogenic activity towards endothelial 
cells. 
 
3.2.1  Interaction of VEGF165 and GAG derivatives 
 
The interaction of solute GAG derivatives with immobilized VEGF165 was analyzed in real-time 
using SPR. While HA showed only a weak interaction with VEGF165, a higher sulfation and 
concentration of the polymeric GAG derivatives led to higher binding levels with sHA3 
exhibiting the highest binding strength (Figure 3.6 A). Interestingly, sHA derivatives revealed 
higher binding levels compared to CS derivatives with a different sugar backbone but a 
comparable degree of sulfation. Furthermore, the shape of the binding curve for sCS3 differed 
from all other GAG derivatives, as during the association phase the curve rises more steeply 
(Figure 3.6 C and D). To determine the minimal binding sequence of GAGs required for 
VEGF165 binding and the sulfation patterns that contribute to the interaction, different oligomeric 
sHA derivatives were investigated for their interaction with immobilized growth factor. Ranking 
of binding levels for the oligomeric derivatives revealed the following binding strength to 
VEGF165: HA dp4 < sHA2Δ6s dp4, psHA dp6 < sHA1 dp4 < psHA dp4 (Figure 3.6 B). Thus, 
intermediately sulfated sHA2Δ6s dp4 with no sulfation at the C6 position of the GlcNAc 
displayed a lower binding strength compared to low sulfated sHA1 dp4. Interestingly, 
tetrameric psHA showed a higher binding strength compared to its hexameric counterpart.
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Figure 3.6. Interaction of immobilized VEGF165 with different concentrations of solute GAG derivatives 
(1-100 µM D.U.) as determined by SPR. Binding levels for the interaction of (A) polymeric and (B) 
oligomeric GAGs to VEGF165 were recorded 10 s before the injection stopped. All values represent the 
mean ± SD of n = 4, are given as relative to baseline response and corrected for the respective molecular 
weight of GAG derivatives. Two-way ANOVA: *p < 0.05; **p < 0.01; ***p < 0.001 vs. respective treatment; 
##p < 0.01; ###p < 0.001 vs. (A) HA or (B) HA dp4. Sensorgrams for the interaction of immobilized VEGF165 
and (C) 100 µM D.U. polymeric GAG derivatives as well as (D) 1, 10 and 100 µM D.U. sCS3. One 
representative sensorgram out of three independent measurements is shown. 
 
In addition to SPR binding analyses, ELISA studies with a reverse experimental set-up in terms 
of the respective immobilized interaction partner were performed. This was done to support 
SPR data and to exclude immobilization effects detrimental for the VEGF165/GAG interaction. 
Biotinylated polymeric GAG derivatives were immobilized to polystyrene surfaces via 
neutravidin and incubated with different concentrations of solute VEGF165. As in SPR analyses 
these experiments showed a preferred binding of sHA derivatives compared to CS derivatives 
with a similar degree of sulfation, with sHA3 exhibiting the strongest interaction and HA 
showing the weakest one (Figure 3.7). In contrast to SPR analyses, low sulfated sHA1 revealed 
a higher binding strength compared to sCS3. Hep with an intermediate degree of sulfation of 
2.2 was used as a native control GAG and showed a binding strength intermediate between 
low sulfated CS and over sulfated sCS3 but also a lower binding strength compared to sHA1. 
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Figure 3.7. Interaction of solute VEGF165 with immobilized polymeric GAG derivatives determined via 
sandwich ELISA using specific antibodies. Biotinylated GAGs were immobilized via neutravidin to 96 
well microtiter plate wells and incubated with different concentrations (0 - 100 ng/ml) of VEGF165. 
Supernatants were used to determine the amount of VEGF165 not bound to GAGs. Values represent the 
mean ± SD of n = 3. 
 
3.2.2 VEGF165 receptor binding 
 
The influence of VEGF165/GAG interaction on the ability of VEGF165 to bind to its primary 
angiogenic receptor VEGFR-2 was determined using SPR. The interaction strength of VEGF165 
to VEGFR-2 decreased with increasing concentration and sulfation of the GAG derivatives  
(HA ≤ CS < sHA1 < Hep < sCS3 < sHA3; Figure 3.8). For Hep, sCS3, and sHA3 lower 
concentrations were already sufficient to strongly interfere with or completely block receptor 
binding. Among all derivatives sHA3 had the strongest impact on VEGF165/VEGFR-2 
interaction. 
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Figure 3.8. Binding of VEGF165 to immobilized VEGFR-2 after pre-incubation with different polymeric 
GAG derivatives. Relative binding of 20 nM VEGF165 to VEGFR-2 alone and after pre-incubation with 
(A) 2, 20 and 200 µM D.U. of HA, CS and sHA1 as well as (B) 0.02, 0.2, 2 and 20 µM D.U. Hep, sCS3 
and sHA3. Binding levels were recorded 10 s before injection stop. Values represent the mean ± SD of 
n = 3 and are given relative to baseline response. Two-way ANOVA: *p < 0.05; ***p < 0.001 vs. 
respective treatment; #p < 0.05; ###p < 0.001 vs. VEGF165 alone; a, p < 0.05 vs. sCS3; b, p < 0.001 vs. 
sHA3. Sensorgrams for the binding of 20 nM VEGF165 to VEGFR-2 alone and in after pre-incubation with 
(C) 200 µM D.U. HA, CS and sHA1, and (D) 20 µM D.U. Hep, sCS3 and sHA3. One representative 
sensorgram out of three independent measurements is shown. 
 
The minimal binding sequence required to interfere with VEGF receptor binding was 
determined using oligomeric GAG derivatives. Furthermore, the influence of the sulfation 
pattern was analyzed. As observed for polymeric HA, VEGF165 binding to VEGFR-2 was 
significantly inhibited by 200 µM D.U. HA dp4 but the inhibition was weak compared to psHA 
dp4 and Hep dp6 at concentrations of 20 - 200 µM D.U. (Figure 3.9). For the sulfated 
derivatives the inhibitory effect at this concentration was comparably strong, in contrast to 
observations with polymeric GAGs where sHA3 showed a stronger inhibition than Hep. 
However, higher concentrations of oligomeric GAGs were required to achieve an inhibitory 
effect on VEGF165 receptor binding. 
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Figure 3.9. Binding of VEGF165 to immobilized VEGFR-2 after pre-incubation with different oligomeric 
GAG derivatives. Relative binding of 20 nM VEGF165 to VEGFR-2 alone and after pre-incubation with 
0.2, 2, 20 and 200 µM D.U. of HA dp4, psHA dp4 and Hep dp6. Binding levels were recorded 10 s before 
injection stop. Values represent the mean ± SD of n = 3 and are given relative to baseline response. 
Two-way ANOVA: **p < 0.01; ***p < 0.001 vs. respective treatment; ##p < 0.01; ###p < 0.001 vs. VEGF165 
alone. 
 
3.2.3 VEGFR-2 phosphorylation 
 
To analyze the consequences of impaired binding of VEGF165 to VEGFR-2 in the presence of 
sulfated GAG derivatives, VEGF165-mediated phosphorylation of the receptor was analyzed. In 
the presence of HA, sHA1, sCS3 and Hep no clear influence on VEGFR-2 phosphorylation in 
comparison to VEGF165 alone could be determined (Figure 3.10). In contrast, sHA3 displayed 
a significant inhibitory effect on receptor phosphorylation comparable to the VEGFR-2 inhibitor 
SU1498. In the presence of sCS3 VEGFR-2 phosphorylation was reduced as well compared 
to VEGF165 alone, but not significantly and therefore not comparable to SU1498.  
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Figure 3.10. Influence of GAG derivatives on VEGF165-mediated phosphorylation of VEGFR-2. HUVEC 
cells were stimulated with VEGF165 alone or pre-formed VEGF165/GAG complexes for 10 min. Cells were 
lysed afterwards and the amount of total and phosphorylated VEGFR-2 was determined in a sandwich 
ELISA. SU1498, a specific VEGFR-2 inhibitor was used as a reference for reduced phosphorylation. 
Values represent the mean ± SD of n = 3. One-way ANOVA: #p < 0.05 vs. Ctrl; **p < 0.01 vs. VEGF165 
alone. 
 
3.2.4 VEGF-mediated sprouting of HUVEC spheroids  
 
The 3D in vitro angiogenesis assay has been used to determine the biological consequences 
of VEGF165/GAG interaction and subsequent inhibition of VEGFR-2 binding and activation. 
HUVEC spheroids were treated with VEGF165 alone or pre-formed VEGF165/GAG complexes. 
Treatment with VEGF165 led to the formation of numerous sprouts compared to the untreated 
control (Figure 3.11). In the presence of HA and Hep no change in sprouting behavior of 
spheroids compared to VEGF165 treatment was observed. In contrast, sCS3 and sHA3 
significantly inhibited VEGF165-mediated spheroid sprouting as displayed by a reduced 
cumulative sprouting length and a reduced number of sprouts (Figure 3.11 B and C). 
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Figure 3.11. Biological consequences of VEGF165/GAG interaction on VEGF165-mediated sprouting of 
HUVEC spheroids. Cells were seeded in medium containing 10% methyl cellulose to form spheroids, 
which were embedded in methyl cellulose/collagen-I gels and treated with VEGF165 alone or pre-formed 
VEGF165/GAG complexes. (A) Sprouting of HUVEC spheroids determined by light microscopy. (B) 
Cumulative sprouting length calculated using ImageJ and (C) number of sprouts. For (A) one 
representative microscope picture is shown and for (B) and (C) values represent the mean ± SD of n 
= 3. One-way ANOVA: ***p < 0.001 vs. VEGF165 alone; ###p < 0.001 vs. Ctrl. 
 
3.3 Impact of GAG derivatives on bFGF signaling 
 
bFGF was one of the first Hep-binding growth factors that were found to stimulate endothelial 
cell proliferation in vitro and in vivo [231]. HSPGs protect bFGF from inactivation in the 
extracellular environment and modulate its bioavailability [184,232]. Furthermore, they are 
required for a correct presentation of bFGF to FGFRs, leading to the formation of 
HSPG/bFGF/FGFR ternary complexes [126]. As bFGF is one of the major angiogenic growth 
factors and plays an important role during wound healing, its interaction with different 
chemically sulfated GAG derivatives was characterized. The impact of GAGs on bFGF 
biological activity regarding its binding to FGF receptor 1 (FGFR1) and the activation of 
endothelial cells (HUVECs) was determined as well. 
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3.3.1  Interaction of bFGF and GAG derivatives 
 
Direct interaction of immobilized bFGF and solute GAG derivatives was examined using SPR. 
A concentration- and sulfation-dependent binding of GAG derivatives to bFGF was observed. 
Polymeric sHA and CS derivatives with a comparable degree of sulfation (sHA1 and CS, sCS3 
and sHA3) displayed comparable binding strength to the growth factor (Figure 3.12 A). The 
binding curve for sCS3 was different from the other GAG derivatives as it already plateaued 
during association where for all other GAGs the curve was still rising (Figure 3.12 C and D). 
For oligomeric GAGs the binding increased with increasing degree of sulfation as well (Figure 
3.12 B). As shown for VEGF165, sHA2Δ6s dp4 un-sulfated at the C6 position of the GlcNAc 
displayed a lower binding strength compared to C6-sulfated sHA1 dp4. Likewise, psHA dp4 
had a considerably higher binding strength for bFGF than psHA dp6. 
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Figure 3.12. Interaction of immobilized bFGF with different concentrations of solute GAG derivatives (1-
100 µM D.U.) as determined by SPR. Binding levels for the interaction of (A) polymeric and (B) 
oligomeric GAGs to bFGF were recorded 10 s before the injection stopped. All values represent the 
mean ± SD of n = 4, are given as relative to baseline response and are corrected for the respective 
molecular weight of GAG derivatives. Two-way ANOVA: **p < 0.01; ***p < 0.001 vs. respective 
treatment; ##p < 0.01; ###p < 0.001 vs. (A) HA or (B) HA dp4. (A) a, p < 0.001 vs. sCS3; b, p < 0.001 vs. 
sHA3; (B) a, p < 0.001 vs. psHA dp4. Sensorgrams for the interaction of immobilized bFGF and (C) 100 
µM D.U. polymeric GAG derivatives as well as (D) 1, 10 and 100 µM D.U. sCS3. One representative 
sensorgram out of three independent measurements is shown. 
 
3.3.2  Effect of GAGs on bFGF stability 
 
The capability of GAG derivatives to protect bFGF from proteolysis was determined by adding 
trypsin to pre-formed bFGF/GAG complexes. Results showed that sHA3 protected bFGF from 
trypsin digestion in a concentration-dependent manner comparable to Hep (Figure 3.13). In 
contrast, HA had no protease protecting effect on bFGF. 
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Figure 3.13. Influence of GAG derivatives on proteolytic degradation of bFGF. 3 µg/ml bFGF was 
incubated with 1, 10, 50 and 100 µg/ml GAG derivative and 600 ng/ml trypsin for 3 h at 37°C. Samples 
were applied to SDS-PAGE and bFGF was visualized using silver staining. One representative gel out 
of three independent experiments is shown. 
 
3.3.3 bFGF receptor binding 
 
To determine the impact of bFGF/GAG interaction on the receptor binding of bFGF, FGFR1IIIc 
was immobilized onto a C1 sensor chip surface and solute bFGF/GAG complexes were 
injected. Binding of bFGF to FGFR1IIIc was suppressed with increasing GAG sulfation and for 
most of the tested polymeric derivatives with increasing concentration (Figure 3.14). sHA1 
showed a stronger inhibitory effect compared to CS even though they had a similar binding 
strength for bFGF alone (see section 3.3.1). Hep exerted a strong inhibitory effect on bFGF 
binding to its receptor, comparable to high sulfated sHA3 and sCS3. HA showed a significant 
inhibition of bFGF binding compared to bFGF without GAG at 0.2 µM D.U., which was not 
observed at higher concentrations. Interestingly, for sHA3 the binding response increased 
again at concentrations above 0.2 µM D.U.  
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Figure 3.14. Binding of bFGF to immobilized FGFR1IIIc after pre-incubation with different polymeric 
GAG derivatives. Relative binding of 40 nM bFGF to FGFR1IIIc alone and after pre-incubation with (A) 
0.2, 2 and 20 µM D.U. of HA, CS, sHA1, Hep, sCS3 and sHA3. Binding levels were recorded 10 s before 
injection stop. Values represent the mean ± SD of n = 3 and are given relative to baseline response. 
Two-way ANOVA: ***p < 0.001 vs. respective treatment; a, p < 0.001 vs. HA; b, p < 0.001 vs. CS; ##p 
< 0.01; ###p < 0.001 vs. bFGF alone. (B) Sensorgram for the binding of bFGF to FGFR1IIIc in the 
presence of 0.2 µM D.U. GAG. One representative sensorgram out of two independent measurements 
is shown. 
 
Oligomeric derivatives were used to determine the minimal binding sequence required for 
interference with binding of bFGF to FGFR1IIIc. For the tetrameric HA an inhibition compared 
to bFGF alone was observed that significantly increased with higher concentrations (Figure 
3.15). psHA dp4 suppressed binding as well but showed a significantly higher impact compared 
to HA dp4 only for 20 µM D.U. In contrast, all concentrations of Hep dp6 caused a strong 
inhibition, which was even more pronounced for psHA dp6. Compared to binding of VEGF165 
to VEGFR-2 (see section 3.2.2), psHA dp4 and Hep dp6 caused a stronger inhibition on bFGF 
binding to FGFR1IIIc. 
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Figure 3.15. Binding of bFGF to immobilized FGFR1IIIc after pre-incubation with different oligomeric 
GAG derivatives. (A) Relative binding of 40 nM bFGF to FGFR1IIIc alone and after pre-incubation with 
0.2, 2, and 20 µM D.U. of HA dp4, psHA dp4, psHA dp6 and Hep dp6. Binding levels were recorded 10 
s before injection stop. Values represent the mean ± SD of n = 3 and are given relative to baseline 
response. Two-way ANOVA: **p < 0.01; ***p < 0.001 vs. respective treatment; a, p < 0.001 vs. HA dp4; 
#p < 0.05; ###p < 0.001 vs. bFGF alone. 
 
3.3.4 Biological consequences of bFGF/GAG interaction 
 
The 3D in vitro angiogenesis assay was used to evaluate the consequences of bFGF/GAG 
interaction on the biological activity of bFGF. Treatment of HUVEC spheroids with bFGF 
induced distinct sprouts compared to the control (Figure 3.16). In the presence of HA, there 
was no difference in sprouting behavior compared to treatment with bFGF alone. In the 
presence of Hep a trend for an increased sprouting was observed. However, sCS3 and sHA3 
suppressed the bFGF-induced sprouting of HUVEC spheroids significantly, displayed by a 
reduced cumulative sprouting length and a decreased number of sprouts (Figure 3.16 B and 
C). 
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Figure 3.16. Biological consequences of bFGF/GAG interaction as determined by a 3D in vitro 
angiogenesis assay. (A) Sprouting of HUVEC spheroids evaluated by light microscopy. (B) Cumulative 
sprouting length calculated using ImageJ and (C) number of sprouts. For (A) one representative 
microscope picture is shown and for (B) and (C) values represent the mean ± SD of n = 3. One-way 
ANOVA: **p < 0.01; ***p < 0.001 vs. bFGF alone; ###p < 0.001 vs. Ctrl. 
 
3.4 Growth factor-independent effects of GAG derivatives 
 
The focus of this part of the thesis is on the effects of GAGs observed without exogenous 
addition of the growth factors TGF-β1, VEGF165 or bFGF and is therefore designated as growth 
factor-independent effects. GAGs were investigated for their ability to bind and activate growth 
factor signaling receptors (VEGFR-2 and FGFR1IIIc), for cytotoxic effects on fibroblast and 
endothelial cells and for their ability to induce angiogenesis. 
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3.4.1 Binding and activation of growth factor receptors  
 
To assess direct interactions of GAG derivatives with growth factor receptors VEGFR-2 and 
FGFR1IIIc, SPR binding studies with immobilized receptors and solute GAG derivatives were 
performed. Regarding VEGFR-2 a binding of sHA3, sCS3 and psHA dp4 was observed, which 
was, however, considerably lower compared to VEGF165 alone (Figure 3.17 A). Likewise, an 
interaction of sHA3, sCS3 and psHA dp4 with immobilized FGFR1IIIc was detected (Figure 
3.17 B). Binding of Hep (polymeric and oligomeric) occurred as well but was lower compared 
to all other sulfated GAGs. Although binding strength of GAG derivatives was lower compared 
to bFGF alone, the interaction of GAGs with FGFR1IIIc was more pronounced than with 
VEGFR-2. 
 
Figure 3.17. Direct interaction of solute GAG derivatives with immobilized growth factor receptors. 
Sensorgrams for binding of GAGs to immobilized (A) VEGFR-2 and (B) FGFR1IIIc. One representative 
sensorgram out of three independent measurements is shown. 
 
Since a weak interaction might already be sufficient for GAGs to activate the receptors, 
VEGFR-2 phosphorylation was evaluated after HUVEC cells were incubated with 200 µM D.U. 
GAGs. However, GAG derivatives alone did not induce phosphorylation of VEGFR-2 (Figure 
3.18). 
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Figure 3.18. Influence of GAG derivatives alone on VEGFR-2 phosphorylation. HUVEC cells were 
stimulated with GAGs for 10 min. Cells were lysed afterwards and the amount of total and 
phosphorylated VEGFR-2 was determined in a sandwich ELISA. Values represent the mean ± SD of n 
= 2. One-way ANOVA: #p < 0.05 vs. Ctrl; *p < 0.05 vs. VEGF165. 
 
3.4.2 Effects on metabolic activity and cell death 
 
sHA3 has been shown to have a strong impact on growth factor-mediated effects (see section 
3.1, 3.2 and 3.3). To evaluate direct effects of sHA3 on cell viability cells investigated in the 
scope of this thesis were directly incubated with sHA3 and compared to cells treated with HA.  
 
3.4.2.1 Hs27 fibroblast cells 
 
Hs27 fibroblast cells that were used for western blot experiments regarding TGF-β1 mediated 
phosphorylation of TβR-I and activation of second messenger molecules were treated with HA 
or sHA3. Fibroblasts showed a significantly reduced (~ 30%) metabolic activity when incubated 
with sHA3 compared to HA and untreated cells (Figure 3.19 A). However, the number of 
necrotic cells in the supernatants was significantly reduced (~ 50%) in the presence of both 
GAGs compared to the control (Figure 3.19 B). 
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Figure 3.19. Impact of sHA3 on metabolic activity and necrosis of Hs27 fibroblasts. Cells were cultivated 
in the presence or absence of 100 µg/ml HA and sHA3 for 48 h (A) Relative metabolic activity was 
determined using the PrestoBlue® Cell Viability Reagent. (B) LDH activity was assessed in the cell 
culture supernatants as a measure for necrotic cells. Values represent the mean ± SD of n = 3. One-
way ANOVA: (A) **p < 0.01 vs. Ctrl, HA. (B) *p < 0.05 vs. Ctrl. 
 
3.4.2.2 HUVECs 
 
HUVECs that were employed for the 3D in vitro angiogenesis assay regarding the VEGF165- or 
bFGF-mediated sprouting of endothelial cell spheroids have been incubated directly with HA 
or sHA3. Experiments showed a significantly increased metabolic activity of cells incubated 
with sHA3 compared to HA (~ 13%) and untreated cells (~ 7%, Figure 3.20 A). Furthermore, 
the number of necrotic cells in the supernatants was reduced in the presence of both GAGs 
compared to the control (~ 11% for HA and ~ 36% for sHA3, Figure 3.20 B). 
 
Figure 3.20. Impact of sHA3 on metabolic activity and necrosis of HUVECs. Cells were cultivated in the 
presence or absence of 100 µg/ml HA and sHA3 for 48 h (A) Relative metabolic activity was determined 
using the PrestoBlue® Cell Viability Reagent. (B) LDH activity was assessed in the cell culture 
supernatants as a measure for necrotic cells. Values represent the mean ± SD of n = 3. One-way 
ANOVA: (A) **p < 0.01 vs. HA. (B) *p < 0.05 vs. Ctrl. 
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3.4.3  Effects on HUVEC spheroid sprouting 
 
GAGs are reported to influence angiogenesis not only by interaction with pro-angiogenic 
growth factors but also by binding to pro-angiogenic receptors [52]. Therefore, effects of GAGs 
on angiogenesis independent of the investigated angiogenic growth factors VEGF165 and bFGF 
were evaluated.  
When treated with HA, no sprouting of HUVEC spheroids in the 3D in vitro angiogenesis assay 
occurred (Figure 3.21). In contrast, sulfated GAGs stimulated sprouting in a sulfation-
dependent manner. Cumulative sprouting length and sprout number were comparably 
increased by sCS3 and sHA3 (Figure 3.21 B and C). 
 
Figure 3.21. Impact of GAG derivatives on sprouting of HUVEC spheroids as determined in a 3D in vitro 
angiogenesis assay. VEGF165 was used as a positive control for spheroid sprouting. (A) Sprouting of 
HUVEC spheroids determined by light microscopy. (B) Cumulative sprouting length calculated using 
ImageJ and (C) number of sprouts. For (A) one representative microscope picture is shown and for (B) 
and (C) values represent the mean ± SD of n = 3. One-way ANOVA: **p < 0.01; ***p < 0.001 vs. Ctrl. 
 
In SPR experiments a weak binding of sulfated GAGs to VEGFR-2 was detected (see section 
3.4.1). To evaluate whether this interaction initiates the pro-angiogenic effect of GAGs 
observed, the 3D in vitro angiogenesis assay with neutralized VEGFR-2 was performed. 
Sprouting of HUVEC spheroids was suppressed in the presence of 10 µg/ml anti-VEGFR-2 
antibody (Figure 3.22). The addition of sCS3 and sHA3 in the presence of anti-VEGFR-2 
antibody showed a comparable sprouting intensity as observed for GAGs alone. 
Results   
67 
 
 
Figure 3.22. Role of VEGFR-2 for the pro-angiogenic effect of GAG derivatives on HUVEC spheroid 
sprouting as determined in a 3D in vitro angiogenesis assay. Cells were treated with a VEGFR-2 
neutralizing antibody (VEGFR-2 Ab) and GAGs. (A) Sprouting of HUVEC spheroids determined by light 
microscopy. (B) Cumulative sprouting length calculated using ImageJ and (C) number of sprouts. For 
(A) one representative microscope picture is shown and for (B) and (C) values represent the mean ± SD 
of n = 3. One-way ANOVA: *p < 0.05; **p < 0.01; ***p <0.001 vs. VEGF + VEGFR-2 Ab. 
 
Besides the binding of GAG derivatives to VEGFR-2, an even more pronounced binding to 
FGFR1IIIc was detected in SPR studies. To analyze whether this interaction causes the 
observed pro-angiogenic effects of GAGs on spheroid, sprouting experiments with neutralized 
FGFR1 were performed. For Hep no difference in sprouting was observed in the presence or 
absence of the FGFR1 antibody (Figure 3.23). In contrast, sprouting was significantly reduced 
for sHA3 + FGFR1 antibody and sCS3 + FGFR1 antibody in comparison to sHA3 and sCS3 
without antibody, respectively.  
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Figure 3.23. Role of FGFR1 for the pro-angiogenic effect of GAG derivatives on HUVEC spheroid 
sprouting as determined in a 3D in vitro angiogenesis assay. Cells were treated with a FGFR1 
neutralizing antibody (FGFR1 Ab) and GAGs. (A) Sprouting of HUVEC spheroids determined by light 
microscopy. (B) Cumulative sprouting length calculated using ImageJ and (C) number of sprouts. For 
(A) one representative microscope picture is shown and for (B) and (C) values represent the mean ± SD 
of n = 3. One-way ANOVA: **p < 0.01; ***p < 0.001; vs. bFGF + FGFR1 Ab; a < 0.001 vs. sCS3; b < 
0.001 vs. sHA3. 
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4 Discussion 
 
Chemically modified GAG derivatives are promising candidates for engineering functional 
biomaterials since their sulfate groups modulate the interaction with growth factors, thereby 
influencing their biological activity [117,207–209]. This in turn can affect cellular activities and 
ultimately healing processes. Previous studies employing GAG derivatives in a solute form or 
incorporated in aECMs revealed their great potential in vitro regarding (i) anti-inflammatory and 
immunomodulatory properties towards macrophages and dendritic cells [215,233], (ii) 
enhanced osteogenic differentiation of hMSCs and preosteoblasts [217,218], (iii) altered 
differentiation of fibroblasts to myofibroblasts [118], and (iv) reduced osteoclast differentiation 
and resorptive activity [219]. Animal experiments also showed promising in vivo effects such 
as (v) an improved osseointegration of dental implants in minipigs [220,221], (vi) improved 
bone healing in critical size femoral defects in rats [222] and (vii) accelerated bone defect 
regeneration in femurs of diabetic rats [223].   
However, the underlying mechanisms for the observed effects are not fully elucidated yet. 
When including GAG derivatives in biomaterials it is of importance to understand the 
mechanism of GAGs in modulating the activity of mediators and cells if the aim is to influence 
physiological and pathophysiological processes. Thus, the purpose of this study was to 
characterize the mode of action of GAG derivatives regarding their interaction with selected 
growth factors and subsequent modulation of their biological activity profiles. The growth 
factors studied in their interplay with GAGs were TGF-β1 as it plays an important role during 
all phases of wound healing and, when overexpressed, in the progression of skin fibrosis, as 
well as the angiogenic growth factors VEGF165 and bFGF as the impact of GAG derivatives on 
angiogenesis is largely unclear. The findings will contribute to a deeper understanding of the 
structure-function relationship of GAGs in their interaction with these mediator proteins.  
 
4.1 Interaction of GAG-bound TGF-β1 with TGF-β receptors and resulting consequences 
for the biological activity of TGF-β1 
 
Earlier interaction studies with TGF-β1 and GAG derivatives by Hintze et al. demonstrated 
specific interactions with different binding strength depending on the degree of sulfation and 
carbohydrate backbone of the GAGs, with sHA3 exhibiting the strongest interaction [117]. In 
addition, van der Smissen et al. found an impaired TGF-β1 downstream signaling in the 
presence of sHA using human dermal fibroblasts in in vitro cell culture experiments [118]. They 
showed a reduced translocation of the second messengers Smad2/3 to the nucleus, when 
solute sHA3 was added to the cell culture medium. In silico docking experiments demonstrated 
the receptor binding sites on TGF-β1 to be occupied by tetrameric sHA, preventing the 
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association of TβR-I and -II. However, no experimental proof of these computational 
simulations existed so far. For this reason, TGF-β receptors were included in SPR interaction 
studies with pre-formed TGF-β1/GAG complexes for a deeper understanding of sHAs’ impact 
on TGF-β1:receptor complex formation. The biological consequences of altered TGF-
β1:receptor complex formation were determined on the receptor level by investigating TβR-I 
phosphorylation as well as the phosphorylation of the TβR-I regulated effector proteins Smad2 
[103] and Erk1/2 [234]. The present findings showed that pre-incubation of TGF-β1 with sHA 
derivatives blocked the binding of TGF-β1 in particular to TβR-I (Figure 3.2), but also to TβR-II 
(Figure 3.1). sHA3 revealed the strongest inhibitory effect and completely blocked binding of 
TGF-β1 to TβR-I at 20 µM D.U., while binding to TβR-II was not fully inhibited even at 
concentrations above 200 µM D.U. psHA dp4 as well showed a stronger inhibitory effect on 
the interaction of TGF-β1 with TβR-I compared to TβR-II (Figure 3.3). This is in line with the 
low affinity of TβR-I for TGF-β1 alone (KD=70 µM) determined using SPR, while the affinity of 
TβR-II is considerably higher (KD=190 nM) [235]. The lower affinity of TβR-I is further reflected 
by the three times higher concentration of TGF-β1 that was used to receive a binding response 
comparable to TGF-β1 binding to TβR-II. The interference of GAGs with TβR-I was largely 
dependent on GAG sulfation, pointing to the importance of electrostatics in these interactions.
 However, the inhibition of binding to TβR-I might not be as relevant as to TβR-II, since 
interactions between TGF-β1 and TβR-I in vivo are barely detectable [235]. The present SPR 
results are consistent with the above-mentioned findings predicting a sulfation-dependent 
occupation in particular of the TβR-I binding site of TGF-β1 by molecular modeling [118]. As 
this binding site has a more favorable distribution of positively charged residues, which is 
important for GAG recognition, it is preferred by sHA. However, elongation of GAG molecules 
bound to the TβR-I binding site might impair the interaction of TGF-β1 with TβR-II as well. This 
is due to sterical hindrance since the binding sites are in close proximity. Interestingly, there 
was an increase in the SPR binding response for TGF-β1/sHA3 interaction with TβR-II in the 
presence of concentrations above 20 µM D.U. but not for other sHA derivatives and lower sHA3 
concentrations (Figure 3.1). In addition, a change in the curvature of the sensorgrams 
compared to binding of only TGF-β1 to TβR-II was observed. The slope of the binding curves 
was more linear and binding response did not increase further at concentrations above 200 µM 
D.U. sHA3 (Figure 3.1 B). Clearly, at concentrations above 20 µM D.U. sHA3 the equilibrium 
between association and dissociation of the ligand during ligand injection was not achieved as 
association predominated. A possible reason is that TGF-β1 and sHA3 might have formed 
complexes, able to bind TβR-II even though the binding strength was weaker than for TGF-β1 
alone. This is consistent with previous docking experiments demonstrating that GAGs only 
partially impair TGF-β1 binding to TβR-II [118]. Furthermore for BMP-2, another member of the 
TGF-β superfamily, Hintze et al. showed that GAG-bound BMP-2 was still able to bind to the 
receptor BMPR-IA, which might be the case for TGF-β1/sHA3 complexes and TβR-II as well 
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[207]. Interaction of BMPR-IA with pre-formed BMP-2/GAG complex was energetically less 
favorable with increasing sulfation and was proposed to lead to a lower biological activity, which 
might also be true for TGF-β1.   
In the above-mentioned experiments, TGF-β1/GAG interaction was only determined with either 
TβR-I or –II in two isolated systems. However, TGF-β1:receptor complex formation is described 
as an ordered-sequential assembly mode [99] where both receptors are necessary to form an 
active signaling complex. In vivo different affinities of TGF-β1 to TβR-II and –I dictate the 
following sequential order of complex assembly: TGF-β1 binds TβR-II first, followed by the 
recruitment of TβR-I [96,97]. To closer mimic the in vivo situation sequential SPR experiments 
were performed. Interestingly, a significantly stronger binding of TβR-I to complexes of TβR-
II/TGF-β1/sHA3 and TβR-II/TGF-β1/psHA dp4 was revealed which did not occur in the 
presence of polymeric HA or HA dp4 (Figure 3.4). These findings imply that binding of TβR-I 
to TβR-II/TGF-β1/sHA3 was not blocked by sHA3, but interaction was rather enhanced 
compared to the interaction of TβR-I with TβR-II/TGF-β1 in the absence of GAG. When injected 
consecutively, TGF-β1 bound to TβR-II still had free binding sites for sHA3. A similar effect 
was observed with psHA dp4 even though the TβR-I recruitment effect was lower compared to 
polymeric sHA3. In general, the interaction of GAGs with TβR-II/TGF-β1 was barely visible, 
although the difference for TβR-I binding to the complex with and without GAG was very 
pronounced. This suggests that a few GAG molecules might already be sufficient to stabilize 
the sequential TGF-β1:receptor complex formation. An enhanced TβR-I recruitment to TβR-
II/TGF-β1/sHA3 was also apparent when pre-formed TGF-β1/sHA3 complexes were injected 
in sequential experiments. This emphasizes further the ability of TGF-β1/sHA3 complexes to 
bind TβR-II, which was particularly apparent for sHA3 concentrations above 20 µM D.U.
 The sequential SPR results are supported by molecular modeling data, revealing a 
potential molecular mechanism for the effect of GAGs on the formation of the TGF-
β1:receptor:GAG complex [236]. Depending on the presence or absence of the receptors, 
different binding poses for GAGs on TGF-β1 were determined that interfered with TGF-β1 
receptor binding sites when receptors where not included in docking experiments. In contrast, 
when receptors were included alternative putative binding poses for GAGs were shown. They 
were broadly distributed only in the presence of TβR-II; for TβR-I a clear GAG binding pose 
emerged (Figure 4.1 A). Furthermore, if pre-bound to TβR-II/TGF-β1 sHA oligosaccharides led 
to a more stable interaction with TβR-I compared to non-sulfated HA oligosaccharides. This 
could be explained by electrostatic interactions of GAG carboxyl and sulfate groups with Lys40 
of TβR-I (Figure 4.1 B). The interaction strength increased with sulfation degree (3 vs. 0) and 
chain length (dp8 vs. dp4). As no clear binding pose could be determined for sHA in the 
complex with TβR-II/TGF-β1 in the absence of TβR-I, TGF-β1 might have multiple binding sites 
for the GAG which allows for association of TβR-I to the complex. In line with this a binding 
model in which GAG binding occurs at two distinct sites on the TGF-β1 dimer was proposed 
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by Lyon et al. [114]. Lee et al. confirmed these findings, postulating that the second binding 
site is located on the opposite site of the primary one [116]. 
 
Figure 4.1. Molecular modeling of the TGF-β1/TβR-I/TβR-II/GAG system. (A) Docking results for HA463’ 
dp4 (top 50 solutions, in blue sticks) to TGF-β1/TβR-II (top) and TGF-β1/TβR-II/TβR-I (bottom). TGF-β1 
is shown in yellow, TβR-II in green and TβR-I in grey. The part of the system not used for docking 
calculations (TβR-I and TβR-II on the right side of TGF-β1) is transparent. (B) Zoomed view of the 
residue Lys40 of TβR-I (in thick sticks, carbons in cyan) that interacts with the negatively charged groups 
of HA463’ dp4 (in thick sticks, carbons in orange). Protein is shown in cartoon. Results were generated 
by Sergey S. Samsonov and M. Teresa Pisabarro, Structural Bioinformatics, BIOTEC TU Dresden 
(adapted from [236]). 
 
Despite the enhanced association of TβR-I, the receptor complex that formed in the presence 
of sHA3 was inactive as western blot experiments with a fibroblast cell line demonstrated a 
significantly impaired Smad2 phosphorylation in the presence of sHA3 (Figure 3.5 A and B). 
This agrees with previous experiments on immunofluorescence-stained Smad2/3 in primary 
fibroblasts incubated with sHA3 that showed a reduced translocation of these second 
messengers to the nucleus [118]. Moreover, a trend towards a decreased phosphorylation of 
TβR-I in the presence of sHA3 was observed for the first time (Figure 3.5 A and C). In the TGF-
β1 pathway, Smad2 and Smad3 are specifically phosphorylated by activated TβR-I [103]. A 
reduced TβR-I phosphorylation due to altered TGF-β1:receptor complex formation might 
therefore lead to a reduced Smad2 phosphorylation. On the other hand, GAGs had no impact 
on the phosphorylation of Erk1/2 (Figure 3.5 A and D). This might be explained by the fact that 
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Erk1/2 is regulated by a multitude of other factors and is not activated by the Smad pathway 
[44,237].   
An inhibitory effect on TGF-β1 binding to TβR-II and a decreased Smad2 phosphorylation was 
also found in ELISA binding studies and western blot experiments with the sulfated 
polysaccharide fucoidan [238]. However, the concentration of the sulfated polysaccharide was 
lower by a factor of three and TβR-I was not included in these studies. In contrast, Lyon et al. 
demonstrated that Hep and high-sulfated liver HS potentiated the activity of rat kidney 
fibroblasts [114], but the effect was only observed in the presence of α2M and ascribed to an 
antagonistic effect of Hep and HS that rescued the inactivation of TGF-β1 by α2M rather than 
modulating TGF-β1:receptor interaction [114]. The biological activity of TGF-β1 was also 
potentiated by chemically sulfated dextrans in mink lung epithelial cells [239], which was 
explained solely by a protection of TGF-β1 from proteolytic degradation upon binding to 
dextrans, maintaining TGF-β1 in an active form, but not by an effect on TGF-β1:receptor 
complex formation.  
A cytotoxic effect of sHA3 on fibroblast cells leading to a reduced cell number and a subsequent 
lower phosphorylation level was excluded using a cytotoxicity assay (Figure 3.19). Even with 
a 30% lower metabolic activity of cells in the presence of sHA3, no increased cell death could 
be determined. This observation is in line with studies using human mesenchymal stem cells 
and osteoblasts, showing a decreased metabolic activity and proliferation in the presence of 
sHA3 which was associated with cell cycle arrest, but not with cell death [240,241].  
Nevertheless, it should be considered that the simplified SPR settings of the present thesis 
have some possible limitations as the receptors used are Fc-fusion proteins. These dimeric 
forms of TβR-I and TβR-II might form a ligand-independent complex in addition to complexes 
including TGF-β1 due to bivalent interactions between the chimera. On the other hand, it might 
also be of advantage that receptors are already available as dimers as this closer mimics the 
in vivo situation. Still, native receptors are transmembrane proteins with a cytoplasmic tail 
involved in large functional complexes. The present study used just the ECDs of the receptors 
in a simplified in vitro model, allowing only for a part of the complex interplay of the components 
in vivo.  
In summary, in the present thesis GAG derivatives were found to affect complex formation of 
TGF-β1 with its signaling receptors TβR-I and –II. Sequential interaction analysis revealed the 
importance of the order of binding events. Hence GAGs might alter TGF-β1:receptor complex 
formation by blocking the interaction of TGF-β1 with its receptors as well as by partially forming 
a receptor complex that does not activate the Smad signaling pathway. Their inhibitory effect 
on TGF-β1 biological activity might be useful for local interference with TGF-β1 driven fibrotic 
disorders, e.g. hypertrophic scars, either by applying GAG derivatives as pharmaceutical 
agents or as components of functional biomaterials to modify wound healing processes.
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4.2 Interaction of VEGF165 with GAG derivatives and consequences for the biological 
activity of the growth factor 
 
Angiogenesis is an important event during tissue healing and highly regulated by the VEGF 
system. Under the influence of VEGF, sprouting occurs in which the ECs branch out and are 
remodeled into a complex network of capillaries, arteries and veins. Pro-angiogenic and anti-
angiogenic effects of GAGs were previously described regarding their impact on VEGF 
bioactivity [52,152,153,158,242]. However, findings are often restricted to Hep, which is known 
for its heterogeneity regarding the carbohydrate backbone, sulfation degree and pattern [41]. 
How GAG derivatives with well characterized structure-function relationships regarding 
biological mediators like BMP-2, sclerostin and OPG [207,208,213] affect angiogenic growth 
factors and thereby the process of angiogenesis was not investigated so far. For this reason, 
angiogenic factors were included in interaction studies and subsequent cell experiments. GAG 
derivatives with different sugar backbone as well as sulfation degree and pattern were 
analyzed in their direct interaction with VEGF165, and the impact of VEGF165/GAG interaction 
on VEGF receptor binding, receptor activation and VEGF165 induced sprouting of HUVEC 
spheroids was determined.  
Polymeric GAG derivatives displayed a concentration- and sulfation-dependent interaction with 
VEGF165 (Figure 3.6 A). Interestingly, a preferred binding of sHA compared to CS derivatives 
with a comparable degree of sulfation was observed, suggesting that the carbohydrate 
backbone of the GAGs significantly influences the interaction. This is in line with findings for 
TGF-β1 [117]) and BMP-2 [207]. The reason for these differences, detected with both SPR and 
ELISA, might be that the different molecular geometries in the carbohydrate backbones of sCS 
(GalNAc) and sHA derivatives (GlcNAc) force the respective sulfated groups to interact 
differently. Furthermore, a difference in the sulfation extent of specific positions within the D.U. 
might be an explanation as well. HA derivatives are completely sulfated at the primary OH-
group at C6 of the GlcNAc, and to a lesser extent on the secondary OH-groups at C2’ and C3’ 
of the GlcA and C4 of the GlcNAc unit. Native CS is a mixture containing 70% CS-4 that is 
highly sulfated at the C4 of the GalNAc before additional sulfation at C6 of GalNAc and at C2’ 
and C3’ of the GlcA occurs, giving rise to sCS3 [209]. Interestingly, the binding curve for sCS3 
has a different shape compared to all other GAG derivatives in their interaction with VEGF165 
(Figure 3.6 C). The curvature of the association phase linearly increased after an initial quick 
binding of sCS3, suggesting a different mode of interaction with VEGF165 compared to sHA. 
This could be also related to differences in the carbohydrate backbone that lead to different 
interactions for sCS derivatives. To clarify this aspect further a kinetic analysis would be 
necessary, but this is difficult with polydisperse, multivalent GAGs where the complexity of 
interactions does not follow a simple 1:1 binding model.  
Besides polymeric GAGs, oligomeric HA derivatives were used in binding studies to determine 
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the minimal binding sequences and to gain more detailed insights into the structural properties 
of sHA contributing to an interaction with VEGF165. SPR interaction analysis showed that dp4 
is sufficient to interact with VEGF165 in a confirmed sulfation-dependent binding similar to that 
observed for polymeric sHA (Figure 3.6 B). Furthermore, the C6 sulfation of the GlcNAc plays 
an important role in this interaction, as the binding strength for the higher sulfated sHA2Δ6s 
dp4 with a non-sulfated C6, was lower than for C6-sulfated sHA1.  
Interestingly, a higher dp does not necessarily enhance binding strength, as binding of psHA 
dp4 was stronger compared to dp6. This indicates that the small tetrasaccharide is able to bind 
to additional GAG binding regions of VEGF165, which is in line with findings for TIMP-3 [210]. 
VEGF is assumed to act as a single entity, forming a single binding surface for the interaction 
with large GAGs [243] so the two identical HBDs of a dimer can be occupied by the same GAG 
chain. Robinson et al. showed that a Hep heptasaccharide is sufficient to fully occupy the Hep 
binding cleft of VEGF [244]. However, when GAGs are smaller the two sites of the dimer are 
assumed to interact with the GAG independently of each other. Consequently, psHA dp4 might 
interact with both VEGF monomers, offering additional binding sites and resulting in a higher 
binding quantity. In contrast to Hep oligosaccharides, psHA dp6 might be sufficient to occupy 
both HBDs. In conclusion, the binding strength to VEGF165 depends on the specific structural 
features of the oligosaccharides including their degree of sulfation as well as sugar ring 
stereochemistry and conformation. It is important to note that the interaction of VEGF165 and 
GAGs was not hindered by immobilization of the growth factor in SPR studies, as confirmed 
by ELISA in a reverse experimental-setup (Figure 3.7). The slight differences between SPR 
and ELISA results may be due to the lower sensitivity of the latter.  
To evaluate the consequences of the VEGF165/GAG interaction on the ability of VEGF165 to 
bind its main pro-angiogenic receptor VEGFR-2, all three components were included in SPR 
experiments. Receptor binding of VEGF was blocked after pre-incubation with GAGs 
depending on their degree of sulfation (Figure 3.8). An influence of the carbohydrate backbone 
was again detectable, since the inhibition by sHA derivatives was stronger than for CS 
derivatives with comparable degree of sulfation, which agrees with a stronger interaction with 
VEGF165 as detected in the direct SPR interaction studies (Figure 3.6). Binding of VEGF165 to 
VEGFR-2 was completely blocked by sHA3 at concentrations above 2 µM D.U., which was not 
observed for any other GAG. In contrast to TGF-β1 and BMP-2 [207] the curve shape of SPR 
sensorgrams and therefore the binding model did not change. Furthermore, the binding 
response did not increase again above a certain GAG concentration, suggesting that GAG-
bound VEGF165 is not able to bind to VEGFR-2.  
Tetrameric GAGs were already sufficient to interfere with VEGF165 receptor binding (Figure 
3.9), but an inhibitory effect of oligomeric GAGs was visible only at higher concentrations than 
for polymeric GAGs. The inhibition through psHA dp4 and Hep dp6 was comparably strong, 
considering the higher degree of sulfation of psHA dp4 but also the higher dp of Hep dp6. 
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Rother et al. demonstrated a stronger inhibitory effect of psHA dp6 on VEGF165 receptor 
binding compared to psHA dp4 and Hep dp6 [245]. In contrast to psHA dp4, binding of psHA 
dp6 to both HBDs might interfere with the VEGFR-2 binding site thereby and lead to a more 
pronounced blocking of VEGF165 receptor binding.   
A general cytotoxic effect of sHA3 on HUVECs was excluded by cell experiments (Figure 3.20). 
The interaction of VEGF165 with sHA3 and the subsequent blocking of VEGFR-2 binding at 
concentrations above 2 µM D.U. led to a decreased VEGFR-2 mediated biological activity. This 
was seen as an impaired phosphorylation of VEGFR-2 (Figure 3.10) in monolayer culture and 
a reduced sprouting of HUVEC spheroids in a 3D cell assay (Figure 3.11), though angiogenesis 
was not completely abolished. A trend for reduced phosphorylation in the presence of sCS3 
was observed as well (Figure 3.10), which may be due to the fact that sCS3 did not completely 
block the interaction of VEGF165 with VEGFR-2. However, sprouting of EC spheroids was 
significantly reduced in the presence of sCS3 (Figure 3.11). The high-sulfated GAG derivatives 
therefore exerted anti-angiogenic effects regarding the activity of VEGF165.  
Interestingly, sHA1 did not lead to a reduced phosphorylation of VEGFR-2 (Figure 3.10) even 
though it strongly inhibited interaction of VEGF165 with the receptor at 200 µM D.U. (Figure 3.8). 
Still, no complete blocking was observed, even at the highest sHA1 concentration analyzed by 
SPR. Free VEGF165 might thus still be able to interact with the receptor, leading to an activation 
and subsequent signal transduction. For Hep there was also no effect on receptor activation 
(Figure 3.10) and HUVEC spheroid sprouting (Figure 3.11), even though a pronounced 
blocking effect on receptor binding was observed in biophysical analysis. These opposing 
results might be because, in contrast to SPR experiments where VEGF165 and VEGFR-2 are 
the only interaction partners for the GAGs, in in vitro cell culture experiments sHA1 and Hep 
might also interact with other proteins present in the experimental setup. These could be 
growth factors present in the serum, other ligands on endothelial cell surfaces or proteins 
secreted by the cells, counteracting the effect on VEGF165. This is in line with the fact that sHA1 
and Hep are weaker VEGF165 binders compared to sCS3 and sHA3, which showed an 
inhibitory effect on VEGFR-2 phosphorylation (Figure 3.8). The literature mostly describes 
beneficial effects for Hep on growth factor/receptor interactions, but differences between Hep 
sources can lead to high structural variability, resulting in different outcomes for in vitro 
experiments [153,156]. Furthermore, in contrast to the degree of sulfation, the sulfation pattern 
of Hep used in the present thesis could not be determined due to the low amounts available 
commercially. Together with a lack of knowledge on the composition of the different Hep 
formulations used in the literature, this hampers a direct comparison of the respective findings.
 Interestingly, in the presence of HA a slight decrease in VEGFR-2 phosphorylation was 
observed (Figure 3.10), but as the blocking effect on VEGF165 receptor binding in SPR analysis 
was marginal (Figure 3.8), this might be due to a different mechanism. As HA is twice the size 
of the sulfated GAG derivatives used in this study it might shield VEGF165 from interaction with 
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VEGFR-2 due to sterical effects. Zhou et al. found HA to influence VEGFR-2 mRNA expression 
in a rabbit model, which could also explain the tendency for lower VEGFR-2 phosphorylation 
in the presence of HA [246].  
It is of note that the conducted in vitro VEGFR-2 phosphorylation study has potential limitations. 
The ELISA only shows an overall phosphorylation signal in contrast to a western blot analysis 
that shows phosphorylation at specific tyrosine residues and is consequently more specific. 
The 3D in vitro angiogenesis assay might be more robust and lead to more consistent and 
significant results than the 2D cell culture system employed to determine VEGFR-2 
phosphorylation. It has been demonstrated that endothelial cells maintained in 2D cell culture 
tend to progressively lose their differentiated phenotype, as can exemplarily be deduced from 
the loss of CD34 expression [247,248].  
In summary, GAGs impair the biological activity of VEGF165 by interfering with receptor binding, 
activation and subsequent downstream signaling as illustrated in Figure 4.2 These findings 
suggest a potential local application of GAGs in a solute form or as part of biomaterials, e.g. 
functional wound dressings, to rebalance excessive angiogenesis associated with 
VEGF165/VEGFR-2 signaling found in conditions like rheumatoid arthritis or diabetic 
retinopathy [249,250]. 
 
Figure 4.2. Simplified scheme of GAGs’ impact on VEGF165 biological activity. (A) Binding of VEGF165 to 
the ECD of VEGFR-2 induces VEGFR-2 dimerization, initiating the autophosphorylation of intracellular 
tyrosine residues. Subsequent activation of the downstream signaling cascade activates EC survival, 
migration and proliferation. (B) Sulfated GAGs (sHA3, sCS3) bind to VEGF165 resulting in a decreased 
VEGF165/VEGFR-2 complex formation. Consequently VEGFR-2 phosphorylation and EC activation are 
impaired. 
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4.3 Interaction of bFGF with GAG derivatives and consequences for the biological activity 
of bFGF 
 
Besides VEGF165, bFGF is another important angiogenic growth factor and one of the best-
studied Hep-binding proteins. HSPGs are known to regulate bFGF signaling by direct 
molecular association with bFGF and the FGF receptors [191,251,252], but the interaction of 
GAG derivatives with bFGF and the consequences for the bFGF/receptor system are 
addressed here for the first time. In direct SPR interaction studies a concentration- and 
sulfation-dependent binding of GAG derivatives was observed (Figure 3.12 A), which is in line 
with VEGF165 and other mediators investigated in previous studies [117,207–209]. In contrast 
to VEGF165, BMP-2 and TGF-β1, bFGF had a comparable binding strength for CS and sHA1 
as well as for sCS3 and sHA3. This suggests that at a comparable degree of sulfation, the 
carbohydrate backbone has no major influence on the bFGF/GAG interaction. Instead it 
appears to be primarily driven by electrostatic interaction between the positively charged amino 
acids of bFGF and the negatively charged sulfate and carboxylic groups of GAGs [253]. 
However, a difference in the shape of sCS3 binding curve was observed (Figure 3.12 C): the 
equilibrium between association and dissociation for the sCS3/bFGF interaction is reached at 
lower concentrations and the dissociation is slower for sCS3 than sHA3. As for the interaction 
with VEGF165 this could be related to differences in the carbohydrate backbone causing sCS 
derivatives to interact differently. Again, a kinetic analysis would be necessary for clarification 
that is again difficult with the polydisperse, multivalent GAGs.   
As found in VEGF165 binding studies with oligomeric GAGs, sulfation of the C6 position of the 
GlcNAc is critical for the interaction of HA derivatives with bFGF as the binding of a derivative 
with no sulfation in this position showed a significantly weaker interaction strength (Figure 3.12 
B). This demonstrates that not simply the overall negative charge density of the GAG but the 
sulfation pattern is important to alter the interaction with bFGF. As for the VEGF165/GAG 
interaction the binding strength was not enhanced with increasing dp. Since bFGF has two Hep 
binding sites at the C-terminus in addition to its canonical binding site [182], psHA dp4 might 
bind to these additional regions of bFGF, which is consistent with observations for VEGF165 
and TIMP-3 [210].  
Like other growth factors, purified FGFs are structurally and functionally labile proteins, readily 
cleaved by proteases [254] and rapidly inactivated by heat and low pH [183]. In the present 
thesis it could be shown that the interaction with sHA but not HA is beneficial for the proteolytic 
stability of bFGF (Figure 3.13). This is consistent with observations of Coltrini et al. showing a 
protective effect of sulfated GAGs like Hep, HS, and both CS-A and –C compared to unmodified 
HA [255]. Weltrowski et al. demonstrated that the protective effect depends on the  
concentration and overall degree of sulfation, as shown for chitosan and cellulose sulfates 
[256]. Therefore, sulfation of GAGs is an important requirement for protecting bFGF from 
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proteolytic cleavage. Coltrini et al. claimed that GAGs’ protective effect not only depends on a 
steric hindrance masking the whole bFGF molecule and hampering the interaction with the 
enzyme, but on specific interaction with an explicit site in the bFGF molecule that is susceptible 
to trypsin cleavage [255].  
However, binding of bFGF to its receptor was blocked by GAGs in a sulfation dependent 
manner (Figure 3.14), as a consequence of the bFGF/GAG interaction (Figure 3.12). 
Interestingly, even if the inhibitory effect was very pronounced for all sulfated GAGs no 
complete blocking was observed. Inhibition by sulfated GAGs was stronger compared to the 
VEGF165/GAG interaction with VEGFR-2, displayed by considerably lower binding levels. As 
for VEGF165/GAG interaction, the inhibitory effect of sHA1 was significantly stronger compared 
to CS. Here the sulfation of the C6 position in GlcNAc of sHA1, which was shown to play an 
important role in bFGF/GAG interaction, had a stronger impact on bFGF/FGFR1IIIc interaction 
compared to the C4 sulfation in GlcNAc of CS. The blocking capacity of sCS3 and sHA3 was 
similar, on the other hand. This suggests a minor influence of the carbohydrate backbone on 
bFGF interaction with FGFR1IIIc in the presence of GAG derivatives, but a major influence of 
the overall degree of sulfation. Surprisingly, the binding response for bFGF/sHA3 up to 200 µM 
D.U. slightly increased. In contrast to the TGF-β1/GAG and BMP-2/GAG interaction, which 
showed a similar effect with TβR-II or BMPR-IA, respectively, no change in the binding model 
was observed. The detected binding of sulfated GAGs to FGFR1IIIc might explain the rising 
binding response (Figure 3.17 B). As the GAG concentration increases, a higher amount of 
free GAG might bind to FGFR1IIIc instead of bFGF. In contrast, GAGs did not directly bind to 
TGF-β receptors and BMPR-IA [207].  
The inhibitory effect of oligomeric GAGs on bFGF receptor binding had the following order: 
psHA dp6 > Hep dp6 > psHA dp4 > HA dp4 (Figure 3.15). Even though the binding strength of 
bFGF for psHA dp4 was considerably higher, psHA dp6 exerted a stronger inhibition on bFGF 
receptor binding than psHA dp4. The latter might bind to the additional binding sites of the 
growth factor that do not seem to be involved in receptor interaction unlike psHA dp6, which 
could block receptor binding through sterical hindrance of the interaction with receptor binding 
sites. In contrast to findings on VEGF165 receptor binding, Hep dp6 displayed a stronger 
inhibitory effect than psHA dp4 – though less than psHA dp6 - proving a notable influence of 
the GAG chain length and the degree of sulfation.   
In case of sHA3 and sCS3 a reduced bFGF receptor binding led to a decreased bFGF 
bioactivity in the induction of HUVEC spheroid sprouting (Figure 3.16). Ishihara et al. also 
showed that free Hep inhibited binding of FGF to FGFRs and ascribed this effect to the 
competition of free GAG with cell-associated HSPGs and FGFRs for the binding of bFGF [257]. 
In contrast, Hep did not inhibit spheroid sprouting in the 3D in vitro angiogenesis assay (Figure 
3.16) despite the blocking effect on bFGF receptor binding (Figure 3.14). This might be due to 
the batch-to-batch variability of Hep from different sources and to discrepancies in the 
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experimental setups.   
The present study revealed that GAG derivatives are able to stabilize growth factors but at the 
same time compete with the respective receptors, leading to a reduced biological activity of the 
studied growth factors and therefore to an anti-angiogenic effect.  
A competition of GAG derivatives for binding of growth factors to their respective receptors 
implies that there is also a competition with cell-associated HSPGs, so GAG derivatives might 
be a promising option in therapeutic strategies to inhibit angiogenesis by disrupting the cell-
associated HS-growth factor interaction. In line with this, soluble Hep mimetics sequester 
angiogenic growth factors like VEGF165 and bFGF, thereby competing with endogenous cell 
surface HS and preventing ternary complex formation on the cell surface and receptor 
signaling. Examples for such inhibitors are sulfated phosphomannopentaose PI-88 [258], 
which reached phase III clinical development for hepatocellular carcinoma [259], and the novel, 
more potent compounds based on PI-88 (PG500 series compounds) [260]. PI-88 inhibits 
angiogenic sprouting in vitro [258] and in vivo using the chicken chorioallantoic membrane 
assay [261]. It binds VEGF165 and bFGF with higher affinity compared to HS [243] and thus 
impairs the interaction of bFGF with HS [262] and reduces VEGF165/VEGFR-2 complex 
formation [263]. Another example are so-called glycol-split Heps which exert anti-angiogenic 
activity by binding bFGF and subsequently preventing bFGF/FGFR1 complex formation [264]. 
Sulfated GAG derivatives might exert anti-angiogenic effects both through competition with 
cell-associated HS and growth factor receptors. 
 
4.4 Growth-factor independent effects of GAGs on receptors and cells 
 
In addition to the influence of GAG derivatives on the biological activity of growth factors, 
effects independent of these mediators were also observed. SPR binding studies already 
showed an interaction of sulfated GAG derivatives with VEGFR-2 as well as FGFR1IIIc (Figure 
3.17), and Xu et al. found an in situ interaction of HS with VEGFR-2 using a proximity ligation 
assay [265]. Hep binding to VEGFR-2 was demonstrated in vitro in several studies 
[149,150,156], while in others direct interaction was not observed [158].   
In line with the present study, the interaction of Hep with FGFR1IIIc was also shown by Powell 
et al. [266]. In the present SPR experiments the binding strength of GAGs to the receptors was 
considerably lower compared to the respective growth factors (VEGF165 or bFGF) but with 
differences for the different receptors: GAG interaction with FGFR1IIIc was considerably 
stronger than with VEGFR-2. The weak binding strength of GAGs to VEGFR-2 did not lead to 
receptor activation, and in 2D culture of HUVECs the VEGFR-2 phosphorylation level in the 
presence of sulfated GAGs was comparable to the control without GAGs and stimulating 
factors (Figure 3.18). Interestingly, sulfated GAGs alone (Hep, sHA3, sCS3) were found to 
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induce EC sprouting (Figure 3.21). This finding might be fundamental for the explanation of the 
contradictory data found for growth-factor dependent effects (see section 4.2 and 4.3). Hep 
might exert opposed effects in HUVECs. On the one hand, it distinctly inhibited receptor binding 
of VEGF165 and bFGF by interaction with these growth factors. On the other hand, it had a 
positive effect on HUVEC sprouting independent of VEGF165 and bFGF. There is probably a 
balance between these two effects leading to a neutral outcome on EC activity for Hep, which 
might also be relevant for sHA1. This is further supported by the weaker interaction of Hep and 
sHA1 with the growth factors compared to sCS3 and sHA3. This could mean that only a portion 
of GAGs is bound to the growth factor, while the rest might remain free and thus able to activate 
EC sprouting. In contrast sCS3 and sHA3, which strongly bind to VEGF165 and bFGF, remain 
predominantly growth factor-bound, thus exerting a negative effect on VEGF165 and bFGF-
mediated EC sprouting due to interference with growth factor receptor binding (Figure 3.11 and 
Figure 3.16).  
As potential interaction partners for GAGs that could cause a VEGF165/bFGF-independent, pro-
angiogenic activity, VEGFR-2 and FGFR1 were studied using specific antibodies to prevent 
the receptors from a possible interaction with GAGs. Even though VEGFR-2 was blocked the 
added sulfated GAGs exerted a pro-angiogenic effect (Figure 3.22), suggesting that VEGFR-
2 is not involved in the pro-angiogenic action of sulfated GAGs. This is in line with both the 
results on VEGFR-2 phosphorylation from 2D cell culture in the presence of sulfated GAGs 
and with the low interaction strength found in SPR studies.   
In contrast, blocking of FGFR1 led to an inhibition of sCS3s’ and sHA3s’ pro-angiogenic action 
(Figure 3.23). Regarding the direct interaction of GAGs and FGFRs, Kan et al. demonstrated 
Hep to interact with a specific sequence in one of the immunoglobulin-like loops in the ECD of 
FGFR1 independent of FGF ligand [267], and Gao et al. reported that Hep is able to activate 
FGFR4 by interacting with its ECD [268]. They postulated a multivalent binding of Hep to 
FGFR4 that allowed Hep to interact with Hep-binding proteins, inducing receptor clustering and 
subsequent activation. Nevertheless, Hep alone was shown to be less mitogenic than together 
with FGF [268]. For FGFR1, however, no stimulation by Hep, HA, HS, keratan sulfate, CS, 
fucoidan or dextran in the absence of FGF was observed in rat L6 myoblasts or murine NIH 
3T3 fibroblasts. Schlessinger et al. proposed a “two-end” model in which Hep augments direct 
FGFR-FGFR and secondary FGF-FGFR interactions, showing that in the absence of Hep the 
direct receptor-receptor contacts and secondary ligand-receptor interactions are not sufficient 
for appreciable dimerization [191]. Therefore, the direct effects of sulfated GAG derivatives on 
FGFR1 may be ascribed to the potential of these polysaccharides to bring FGFR1s together to 
form a receptor dimer, which can be efficiently bound by the ligand present in the cell culture 
serum or being released by the cells. GAG derivatives would therefore not directly activate 
FGFR1 themselves but facilitate ligand-dependent activation. According to this assumption 
and as already demonstrated for TGF-β1 and its receptors, the order of binding events in the 
Discussion   
82 
 
interplay of bFGF, GAGs and FGFR1 might also be highly important. In the experiments where 
only GAGs were added without exogenous bFGF, they might bind to FGFR1 prior to 
association with the growth factor from the cell culture serum. Even though the interaction of 
bFGF and GAGs seems to be stronger than for GAGs and FGFR1, bFGF concentrations in the 
serum were much lower compared to SPR interaction studies and therefore a GAG/receptor 
interplay might be possible.  
However, Murray et al. found an example for direct activation of another receptor tyrosine 
kinase through GAGs. They demonstrated that Hep binds specifically to the ECD of the 
receptor Anaplastic lymphoma kinase (ALK) and induces tyrosine autophosphorylation, 
suggesting a role for sulfated GAGs and associated PGs as ligands for ALK [269]. A putative 
Hep-binding motif was revealed in the N-terminal region of ALK that is similar to the motif found 
in FGFRs critical for Heps ability to act as a co-ligand for FGFR activation [191,270]. Oligomeric 
Heps (< dp15) bound ALK in a monovalent manner not activating the receptor, while longer 
Hep chains induced ALK dimerization and activation in neuroblastoma cells [269]. Oversulfated 
Hep and dextran sulfate also induced autophosphorylation of ALK, whereas CS, HS, and 
specifically desulfated Heps did not. In the present study Hep, which directly stimulated EC 
sprouting, did not exert its effect via direct stimulation of FGFR1 (Figure 3.23), while high 
sulfated GAG derivatives did, as shown by receptor blocking studies (Figure 3.14). Moreover, 
sulfated GAG derivatives had a higher affinity for FGFR1 in SPR binding studies compared to 
Hep (Figure 3.17). These results suggest a different mode of action of sulfated GAG derivatives 
compared to native GAGs. Whether they are able to directly activate growth factor receptors 
and/or rather facilitate receptor dimerization and subsequent growth factor association remains 
to be clarified.  
It has to be considered that in the present thesis only one effective concentration of GAG 
derivatives in the 3D in vitro angiogenesis assay was investigated, which was chosen based 
on results of SPR receptor interaction studies. Whether the observed effects are concentration-
dependent needs to be investigated in further experiments.  
In summary, sulfated GAGs did not only exert anti-angiogenic effects regarding the biological 
activity of VEGF165 and bFGF (see section 4.2 and 4.3), they are also pro-angiogenic in the 
absence of exogenous growth factors. The direct activation of FGFR1 independent of the 
investigated growth factors could be one possible reason; alternatively, they may promote an 
enhanced receptor dimerization facilitating the association of growth factors. Nevertheless, 
these pro-angiogenic effects were considerably lower than those of VEGF165 and bFGF alone. 
In addition, GAG derivatives have also been shown to block inhibitors of angiogenesis like 
TIMP-3 [245], also indicating an additional pro-angiogenic effect of GAG derivatives.  
The pro- and anti-angiogenic effects could be translated into GAG-containing biomaterials to 
improve the healing process in patients with chronic wounds. Even though the findings strongly 
suggest a modulatory potential of sulfated GAGs regarding angiogenesis, extensive studies 
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are necessary to reveal whether the anti- or the pro-angiogenic effects determined in isolated 
cell culture models predominate in vivo. 
 
Figure 4.3. Schematic overview of the effects of sulfated GAGs on spheroid sprouting in the presence 
of blocking antibodies against VEGFR-2 and FGFR1. Sprouting in the presence of sulfated GAGs was 
observed with neutralized VEGFR-2, but not with neutralized FGFR1. 
 
Based on the results gained so far, even though no effect on activation of growth factor 
receptors was observed, as in the case of VEGFR-2, it cannot be excluded that there is an 
influence further downstream on the signaling pathway kinases through cellular uptake of GAG 
derivatives. Internalization of sHA mediated by the receptor CD44 and the scavenger receptors 
CD36 and Lox1 in macrophages was demonstrated by Jouy et al. [271], who also found a 
reduced activation of transcription factors like NF-кB. GAG internalization was likewise found 
for hMSCs [241], which corresponds with an increase of endocytosis regulating proteins shown 
for hMSCs cultured on sHA3 [272]. These data point to possible intracellular effects of GAGs 
by influencing kinases involved in signaling pathways.   
Moreover, the variety of mediators involved in angiogenesis that are able to interact with 
Hep/HS in vivo, like angiopoietins, angiogenin or PDGF [52], has to be considered. From the 
findings obtained in the present thesis it cannot be excluded that the effects of GAGs 
designated as direct effects are due to interaction with mediators other than VEGF165 or bFGF 
that are present in the cell culture medium or secreted by the cells.  
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4.5 Future prospects 
 
VEGF165 signaling mainly depends on the activation of VEGFR-2. However, neuropilins are 
involved in mediating VEGF function as coreceptors. Hep/HSPGs bind to the ECD of 
neuropilins and have been proposed to regulate VEGF165 biological activity not only by binding 
VEGF165 directly [273] but also by interacting with NRP-1 [148,154]. Hence, NRP-1 should be 
included in interaction studies with VEGF165, GAG derivatives and receptors as described for 
Hep by Teran and Nugent [158] to closer mimic the in vivo situation and to analyze the 
modulating effect of GAGs on NRP-1 in the VEGF system.  
Since Hep is known to interact with all members of the FGF family, the affinity of several FGFs 
as for instance aFGF (also known as FGF-1) for GAG derivatives should be determined to 
disclose whether the structural and biochemical differences of FGF proteins affect the interplay 
with GAGs. The biological outcome of these interactions regarding especially the FGF:receptor 
complex association would be of great interest for a deeper understanding of the structure-
function relationship of GAG derivatives in their interplay with the FGF/FGFR system.
 Furthermore, an intimate crosstalk is reported for bFGF and VEGF during angiogenesis 
and there is experimental evidence showing that bFGF induces neovascularization indirectly 
by activating the VEGF/VEGFR-2 system. Also, bFGF and VEGF may exert a synergistic effect 
in different angiogenesis models [274]. It is therefore of interest to determine the modulating 
role of GAGs in the VEGF/bFGF crosstalk by characterizing the kinetics and affinity of 
oligomeric GAGs in their interaction with both growth factors as well as their impact on 
bFGF/VEGFR-2 binding to gain further insights into this complex system.  
Potential direct effects of GAGs observed in the present study may be due to GAG/FGFR1 
interaction. To clarify whether GAG derivatives are able to directly activate FGFR1, 
phosphorylation of this receptor in the presence of sulfated GAGs needs to be investigated. In 
addition, it is of great importance to analyze the internalization of GAG derivatives by ECs in 
general and to investigate putative intracellular targets like signaling pathway kinases, to 
determine whether GAGs also influence the biological activity of mediator proteins further 
downstream.  
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5 Conclusion 
 
The aim of the present thesis was to elucidate the structure-function relationship of chemically 
modified GAG derivatives in their interaction with mediator proteins and cells relevant to 
healing processes. The interaction of GAG derivatives with VEGF165 and bFGF was found to 
depend on GAG concentration as well as degree and pattern of sulfation, with sulfation at the 
C6 position of GlcNAc playing an important role in the interaction strength. The carbohydrate 
backbone of GAGs has an additional influence on the interaction with VEGF165, but not with 
bFGF.  
Furthermore, different mechanisms of GAGs in modulating the biological activity of the 
investigated growth factors were revealed (Figure 5.1) that ultimately influenced cellular 
processes like fibrosis and angiogenesis. GAGs exert a dual blocking effect on TGF-
β1:receptor complex formation: they inhibit the interaction of GAG-bound TGF-β1 with TβR-I 
and –II and can also form a sHA3:TGF-β1:receptor complex that does not activate the Smad 
signaling pathway. Consequently, both mechanisms lead to an inhibition of TGF-β1 bioactivity, 
with the effects strongly depending on the order of binding events. Regarding an application of 
GAGs in functional biomaterials for the modulation of wound healing, the findings suggest they 
may be able to interfere with TGF-β1 driven skin fibrosis and thus reduce scarring and 
accelerate the healing process.  
In angiogenic processes GAG derivatives exert effects both dependent on and independent of 
growth factors. On one hand, GAGs bind VEGF165 or bFGF and as a consequence impair 
binding of the growth factors to their cognate receptors, thereby preventing downstream 
signaling. On the other hand, GAGs alone have pro-angiogenic effects on EC sprouting. Again, 
findings point to the importance of the order of binding events, as binding of GAG derivatives 
to growth factors, receptors or both leads to different cellular outcomes regarding signaling. 
Based on the findings of the present thesis a direct FGFR1 activation through sulfated GAG 
derivatives could be a possible reason for the observed growth-factor-independent effect on 
angiogenesis. However, it might also be due to facilitated receptor dimerization allowing for an 
enhanced ligand binding or by interaction with intracellular targets upon GAG internalization, 
which needs to be clarified in further experiments. Whether positive or negative effects on 
angiogenic processes dominate in vivo has to be evaluated by extensive animal studies.
  The obtained results contribute to a better understanding of the modulatory effects of 
GAG derivatives on mediators relevant for healing and will help to further improve the design 
of functional biomaterials that include GAG derivatives to specifically modulate healing 
processes. 
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Figure 5.1. Summary of the effects of GAG derivatives on growth factor/receptor interaction. The 
interaction with GAGs led to an inhibitory effect on the biological activity of all investigated growth factors 
(TGF-β1, VEGF165 and bFGF). Furthermore, growth-factor independent effects of GAGs were observed 
with FGFR1 as a potential direct target for GAG binding, with the underlying mechanisms of direct GAG 
effects needing further clarification. 
Summary   
87 
 
Summary 
 
Age-related pathologies, like chronic wounds and impaired fracture healing are a consequence 
of a longer life expectancy in our aging population and are associated with considerable clinical 
and socioeconomic burdens. To improve the wound healing capacity of patients, the 
development of new adaptive biomaterials to selectively control and promote bone and skin 
regeneration is essential. A promising approach for the design of such biomaterials 
incorporates elements of the extracellular matrix (ECM) that play a role in tissue regeneration. 
Glycosaminoglycans (GAGs) are major ECM components known to interact with important 
mediator proteins, thereby influencing their biological activity and subsequently cellular 
processes. However, native GAGs like heparan sulfate have a limited utility for biomedical 
applications due to their restricted availability, batch-to-batch variability and source-dependent 
biological activity. For this reason, chemically modified hyaluronan (HA) and chondroitin sulfate 
(CS) derivatives with defined properties regarding the carbohydrate backbone, the degree of 
sulfation and the sulfation pattern are preferable for studying their structure-function 
relationship in the interaction with mediator proteins and cells relevant to healing processes. 
The aim of the present study was to investigate how GAGs influence cellular processes - 
directly or indirectly by binding growth factors – and particularly how the sugar backbone as 
well as the sulfation degree and pattern of GAG derivatives influence the interaction and thus 
the biological activity of transforming growth factor (TGF)-β1, and the angiogenic mediators 
vascular endothelial growth factor (VEGF)165 and basic fibroblast growth factor (bFGF). 
Sulfated HA (sHA) and CS derivatives were reported to strongly interact with growth factors 
like bone morphogenetic proteins (BMP)-2/-4 and transforming growth factor (TGF)-β1. The 
bioactivity of the latter was impaired in the presence of highly sulfated HA (sHA3), the 
underlying mechanism of which is so far not fully elucidated. In the present thesis the 
interaction of all components of the TGF-β1:receptor complex with sHA was examined by 
surface plasmon resonance (SPR), showing that pre-incubation of TGF-β1 with sHA 
derivatives blocked the binding of TGF-β1 in particular to TGF-β receptor (TβR)-I, but also to 
TβR-II. In sequential SPR experiments that mimicked the in vivo TGF-β1:receptor complex 
formation more closely, however, recruitment of TβR-I to the TβR-II/TGF-β1 complex was 
significantly stronger if the complex contained sHA3. GAGs thus exert a dual blocking effect 
on TGF-β1:receptor complex formation, with the effects strongly depending on the order of 
binding events. The bioactivity of TGF-β1 in conjunction with sHA at the receptor level, which 
was investigated here for the first time, showed a decrease of phosphorylation for TβR-I and 
the TβR-I-regulated effector protein Smad2 in the presence of sHA3, indicating of the formation 
of an inactive signaling complex.  
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Also analyzed was the structure-function relationship of HA and CS derivatives in their 
interaction with the most important angiogenic growth factors, namely vascular endothelial 
growth factor (VEGF)165 and basic fibroblast growth factor (bFGF). The aim was both to identify 
structural properties that contribute to an interaction and to determine the biological 
consequences of growth factor/GAG interaction. Both growth factors showed a sulfation-
dependent interaction with GAG derivatives in SPR binding analysis. Unlike bFGF, VEGF165 
also showed a clear preference for sHA compared to CS derivatives, indicating that the 
interaction with this growth factor is not only impacted by the degree of sulfation but also by 
the carbohydrate backbone of the GAG. sHA tetramers were sufficient to interact with VEGF165 
and bFGF in SPR measurements. The position of sulfation appears to play an important role 
in the interaction with both angiogenic growth factors, as the binding strength of the sHA 
tetrasaccharide with no C6-sulfation of the N-acetylglucosamine (GlcNAc) was lower 
compared to a derivative exclusively sulfated at the C6 position. Interestingly, binding of 
tetrameric persulfated HA (psHA) was stronger compared to hexameric psHA, indicating that 
the tetrasaccharide is able to bind to additional regions of VEGF165 and bFGF.   
Binding of VEGF165 and bFGF to their respective receptors VEGF receptor (VEGFR)-2 and 
FGF receptor (FGFR) 1 decreased if the growth factors were pre-incubated with sulfated GAGs 
in SPR studies. For VEGF165, an influence of the carbohydrate backbone was visible again, 
since the inhibition of growth factor binding to VEGFR-2 by sHA derivatives was stronger than 
for CS derivatives with comparable degree of sulfation. For bFGF/FGFR1IIIc interaction, 
sulfation of the C6 position in GlcNAc of low-sulfated sHA had a stronger impact compared to 
the C4 sulfation in GlcNAc of CS, while blocking capacity of sCS3 and sHA3 was similar. This 
suggests a minor influence of the carbohydrate backbone on bFGF interaction with FGFR1IIIc 
in the presence of GAG derivatives, but a major influence of the overall degree of sulfation. 
Tetrameric GAGs were already sufficient to interfere with VEGF165 and bFGF receptor binding, 
but the blocking effect was enhanced with increasing sulfation and chain length of the 
derivative. The interaction of VEGF165 with sHA3 and the subsequent blocking of VEGFR-2 
binding led to an impaired phosphorylation of VEGFR-2. Furthermore, the induction of 
endothelial cell spheroid sprouting mediated via VEGF165 or bFGF was diminished by high 
sulfated GAGs as displayed in a 3D in vitro angiogenesis assay. However, angiogenesis was 
not completely abolished. 
Interestingly, GAG derivatives induced the sprouting of endothelial cell spheroids independent 
of the studied angiogenic growth factors. It could be shown that VEGFR-2 is not involved in the 
pro-angiogenic action of sulfated GAGs, while FGFR1 appears to play a role as blocking it 
inhibited the pro-angiogenic effect of sCS3 and sHA3. GAG derivatives might directly activate 
FGFR1 as they bound to the receptor in SPR experiments, but the observed effect might also 
be due to facilitated receptor dimerization with a subsequent enhanced ligand binding, or to an 
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interaction with intracellular targets after GAG internalization; this needs to be clarified in 
further experiments. Findings point to the importance of the order of binding events, as binding 
of GAG derivatives to growth factors, receptors or both leads to different cellular outcomes 
regarding signaling. 
Results of the present thesis show that GAG derivatives employ different molecular 
mechanisms to modulate cellular processes – both directly or indirectly via growth factor binding 
- and contribute to a deeper understanding of their mode of action, which might allow to tune 
the biomaterial composition to patient-specific needs. GAG-containing biomaterials are 
promising candidates to interfere with TGF-β1-driven local skin fibrosis, as they reduce the 
bioactivity of TGF-β1. Concerning the inhibitory effects on VEGF165 and bFGF signaling, an 
application of GAGs to interfere with the excessive angiogenesis, occurring in rheumatoid 
arthritis and diabetic retinopathy could be of interest. Whether these in vitro findings can be 
used to control the biological activity of TGF-β1, VEGF165 and bFGF or to directly stimulate 
angiogenesis independent of growth factors needs to be validated in vivo. 
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Zusammenfassung 
 
Die aufgrund des demografischen Wandels steigende Zahl an Patienten mit Knochendefekten, 
chronischen Wunden und einhergehender Multimorbidität stellt ein großes klinisches und 
sozioökonomisches Problem dar. Derzeitige etablierte Verfahren zur Behandlung von 
Knochen- und Hautdefekten weisen zahlreiche Nachteile auf, weshalb die Erforschung 
innovativer Methoden notwendig ist. Ein vielversprechender Ansatz zur Verbesserung der 
Wundheilungskapazität ist die Funktionalisierung von Biomaterialien mit Komponenten der 
extrazellulären Matrix (ECM), die eine Rolle bei der Geweberegeneration spielen. 
Glykosaminoglykane (GAGs) sind wichtige ECM-Komponenten, von denen bekannt ist, dass 
sie mit Mediatorproteinen interagieren, wodurch sie deren biologische Aktivität und damit 
zelluläre Prozesse beeinflussen. Native GAGs, wie Heparansulfat, sind jedoch aufgrund ihrer 
eingeschränkten Verfügbarkeit, Charge-zu-Charge-Variabilität und ihrer quellenabhängigen 
biologischen Aktivität nur begrenzt für biomedizinische Anwendungen geeignet. Daher sind 
chemisch modifizierte Hyaluronsäure (HA)- und Chondroitinsulfat (CS)-Derivate mit definierten 
Eigenschaften bezüglich des Kohlenhydratrückgrats, sowie des Sulfatierungsgrades und 
-musters besonders geeignet, um ihre Struktur-Eigenschaftsbeziehung in der Interaktion mit 
heilungsrelevanten Mediatorproteinen und Zellen zu untersuchen. Ziel der vorliegenden Arbeit 
war die Untersuchung der zugrundeliegenden molekularen Mechanismen, mit denen GAGs 
zelluläre Prozesse direkt oder indirekt durch Bindung von Wachstumsfaktoren beeinflussen. 
Hierbei sollte vor allem gezeigt werden, wie Kohlenhydratrückgrat, Sulfatierungsgrad und  
-muster der GAG-Derivate die Interaktion und damit die biologische Aktivität des 
transformierenden Wachstumsfaktors (TGF)-β1, sowie der angiogenen Mediatoren vaskulärer 
endothelialer Wachstumsfaktor (VEGF)165 und basischer Fibroblasten-Wachstumsfaktor 
(bFGF) beeinflussen. 
In vorangegangen Studien wurde gezeigt, dass sulfatierte HA- (sHA) und CS-Derivate stark 
mit Wachstumsfaktoren, wie den knochenmorphogenetischen Proteinen (BMP)-2/-4 und TGF-
β1 wechselwirken. Letzterer wies eine beeinträchtigte Bioaktivität in Gegenwart von 
hochsulfatierter HA (sHA3) auf. Der zugrundeliegende Mechanismus wurde bisher nicht 
vollständig aufgeklärt und daher in dieser Arbeit untersucht. Oberflächenplasmonresonanz 
(SPR)-Untersuchungen mit allen Komponenten des TGF-β1:Rezeptor-Komplexes in 
Anwesenheit von GAGs zeigten, dass die Vorinkubation von TGF-β1 mit sHA-Derivaten die 
Bindung von TGF-β1, insbesondere an TGF-β Rezeptor (TβR)-I, aber auch an TβR-II, 
blockierte. In sequentiellen SPR-Experimenten, welche die in vivo-TGF-β1:Rezeptor-
Komplexbildung genauer nachahmen, war jedoch die Rekrutierung von TβR-I zum TβR-
II/TGF-β1-Komplex signifikant stärker, wenn der Komplex sHA3 enthielt. GAGs üben somit 
einen dualen Blockierungsmechanismus auf die TGF-β1:Rezeptor-Komplexbildung aus, 
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wobei die Effekte stark von der Reihenfolge der Bindungsereignisse abhängen. Die hier 
erstmals untersuchte Bioaktivität von TGF-β1 in Verbindung mit sHA auf Rezeptorebene zeigte 
eine Abnahme der Phosphorylierung für TβR-I und das TβR-I-regulierte Effektorprotein Smad2 
in Gegenwart von sHA3, was auf die Bildung eines inaktiven Signalkomplexes hindeutet. 
Ebenfalls analysiert wurde die Struktur-Eigenschaftsbeziehung von HA- und CS-Derivaten in 
ihrer Wechselwirkung mit den wichtigsten angiogenen Wachstumsfaktoren: VEGF165 und 
bFGF. Ziel war es strukturelle Eigenschaften zu identifizieren, die zu einer Interaktion beitragen 
und die biologischen Konsequenzen von Wachstumsfaktor/GAG-Interaktion zu ermitteln. 
Beide Wachstumsfaktoren zeigten eine sulfatierungsabhängige Wechselwirkung mit GAG-
Derivaten in der SPR-Bindungsanalyse. Anders als bFGF zeigte VEGF165 außerdem eine klare 
Präferenz für sHA im Vergleich zu CS-Derivaten, was darauf hindeutet, dass die 
Wechselwirkung mit diesem Wachstumsfaktor nicht nur vom Sulfatierungsgrad, sondern auch 
vom Kohlenhydrat-Rückgrat des GAGs beeinflusst wird. sHA-Tetramere waren ausreichend, 
um mit VEGF165 und bFGF in SPR-Messungen zu interagieren und zeigten, dass die Position 
der Sulfatierung eine wichtige Rolle bei der Interaktion mit beiden angiogenen 
Wachstumsfaktoren zu spielen scheint, da die Bindungsstärke des sHA-Tetrasaccharids ohne 
C6-Sulfatierung des N-Acetylglucosamins (GlcNAc) im Vergleich zu einem ausschließlich an 
der C6-Position sulfatiertem Derivat geringer war. Interessanterweise war die Bindung von 
tetramerer persulfatierter HA (psHA) im Vergleich zu einem psHA-Hexamer stärker, was 
darauf hinweist, dass das Tetrasaccharid in der Lage ist, mit zusätzlichen GAG-
Bindungsstellen von VEGF165 und bFGF zu interagieren.   
Die Bindung von VEGF165 und bFGF an ihre jeweiligen Rezeptoren VEGF Rezeptor (VEGFR)-
2 und FGF Rezeptor (FGFR) 1 war vermindert, wenn die Wachstumsfaktoren in SPR-Studien 
mit sulfatierten GAGs vorinkubiert wurden. Auch hier wurde für VEGF165 ein Einfluss des 
Kohlenhydratrückgrats nachgewiesen, da die Bindung des Wachstumsfaktors an VEGFR-2 
durch sHA-Derivate stärker gehemmt wurde als durch CS-Derivate mit vergleichbarem 
Sulfatierungsgrad. Auch auf die bFGF/FGFR1IIIc-Interaktion hatte die Sulfatierung der C6-
Position des GlcNAc von sHA1 einen stärkeren Einfluss als die C4-Sulfatierung des GlcNAc 
von CS. Im Gegensatz dazu war die Blockierungskapazität von sCS3 und sHA3 jedoch 
ähnlich. Dies deutet auf einen geringen Einfluss des Kohlenhydratrückgrats, jedoch auf einen 
großen Einfluss des gesamten Sulfatierungsgrades der GAG-Derivate auf die bFGF-
Wechselwirkung mit FGFR1IIIc hin. Tetramere GAGs waren ebenfalls ausreichend, um die 
VEGF165- und bFGF-Rezeptorbindung zu stören. Mit zunehmendem Sulfatierungsgrad und 
Länge des Derivats wurde der Blockierungseffekt verstärkt. Die Interaktion von VEGF165 mit 
sHA3 und die anschließende Blockierung der VEGFR-2-Bindung führte zu einer verminderten 
Phosphorylierung von VEGFR-2. In einem 3D in vitro-Angiogenese-Assay zeigte sich darüber 
hinaus eine verminderte VEGF165- bzw. bFGF-vermittelte Sprossung von Endothelzell-
Zusammenfassung   
92 
 
Sphäroiden durch hochsulfatierte GAGs. Die Angiogenese wurde jedoch nicht vollständig 
inhibiert. 
Interessanterweise induzierten GAG-Derivate unabhängig von den untersuchten angiogenen 
Wachstumsfaktoren die Sprossung von Endothelzell-Sphäroiden. Es konnte gezeigt werden, 
dass VEGFR-2 nicht an der proangiogenen Wirkung von sulfatierten GAGs beteiligt ist, 
während die Blockierung von FGFR1 die proangiogene Wirkung von sCS3 und sHA3 hemmt. 
GAG-Derivate könnten FGFR1 direkt aktivieren, da in SPR-Experimenten gezeigt wurde, dass 
sie an den Rezeptor binden. Andererseits könnte der beobachtete Effekt auch auf eine 
erleichterte Rezeptordimerisierung mit einer anschließenden verstärkten Ligandenbindung 
oder die Wechselwirkung mit intrazellulären Targets nach GAG-Internalisierung 
zurückzuführen sein. Dies muss in weiteren Experimenten geklärt werden. Die Ergebnisse 
weisen auf die Wichtigkeit der Reihenfolge der Bindungsereignisse hin, da die Bindung von 
GAG-Derivaten an Wachstumsfaktoren, Rezeptoren oder beide Komponenten zu 
unterschiedlichen zellulären Konsequenzen hinsichtlich der Signalgebung führt. 
In der vorliegenden Arbeit wurde gezeigt, dass GAG-Derivate unterschiedliche molekulare 
Mechanismen nutzen, um zelluläre Prozesse direkt oder indirekt über die Bindung von 
Wachstumsfaktoren zu modulieren und tragen zu einem tieferen Verständnis ihrer 
Wirkungsweise bei. Dies könnte wiederum eine Abstimmung der Biomaterial-
zusammensetzung auf patientenspezifische Bedürfnisse ermöglichen. GAG-haltige Bio-
materialien sind vielversprechend für eine Verminderung TGF-β1-gesteuerter lokaler 
Hautfibrose, da sie die Bioaktivität von TGF-β1 reduzieren. In Bezug auf die inhibitorischen 
Effekte auf die VEGF165- und bFGF-Signaltransduktion könnten GAGs mit übermäßiger 
Angiogenese, die bei rheumatoider Arthritis und diabetischer Retinopathie auftritt, 
interferieren. Ob diese in vitro-Ergebnisse zur Steuerung der biologischen Aktivität von TGF-
β1, VEGF165 und bFGF oder zur direkten Stimulation der Angiogenese unabhängig von 
Wachstumsfaktoren genutzt werden können, muss in vivo validiert werden.  
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